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SUMMARY 
Glycosylation is one of the most common and essential protein modifications in 
cells. This modification plays critical roles in protein folding, trafficking and stability, 
and regulates many cellular events. Abnormal glycosylation is often correlated with 
diseases such as cancer and infectious diseases. The vast majority of extracellular 
proteins are glycosylated; these cell surface and secreted glycoproteins are crucial for 
extracellular interactions, cell signaling and immune response, and also reflect the disease 
and developmental status of the cell. They serve as excellent therapeutic targets due to 
their easy accessibility by small molecules and macromolecules. Secreted glycoproteins 
are also a promising non-invasive source of diagnostic biomarkers, since they exist in 
bodily fluids and can be easily accessed for disease diagnosis and monitoring. 
Due to their critical importance in cellular processes and relevance in disease, 
extracellular glycoproteins contain a wealth of information regarding the molecular 
mechanisms of disease. Comprehensive analysis of these glycoproteins will provide the 
foundation to identify diagnostic biomarkers and therapeutic targets. Modern mass 
spectrometry (MS)-based proteomics enables comprehensive and site-specific analysis of 
protein modifications, including glycosylation. However, global analysis of glycoproteins 
is extremely challenging. Many glycoproteins are present at low abundance in complex 
biological samples, and therefore require effective separation prior to MS-based analysis. 
Furthermore, glycans are highly heterogeneous, and therefore the mass tag necessary to 
pinpoint glycosylation sites is largely unpredictable. 
 xvi 
The work in this thesis focuses on the development of mass spectrometry-based 
methods to globally analyze cell surface and secreted glycoproteins. Chapter 1 provides a 
brief overview of MS-based proteomics and glycoproteomics analysis, including current 
methods and challenges. Chapter 2 describes the novel method developed for site-specific 
analysis of the cell surface N-glycoproteome. Chapter 3 illustrates an application of this 
method to investigate cell surface glycoprotein changes throughout the epithelial-
mesenchymal transition. Chapter 4 focuses on the comprehensive analysis of secreted 
proteins and glycoproteins from Saccharomyces cerevisiae, which is an excellent model 
system for eukaryotic cells. Finally, Chapter 5 provides an enhanced digestion method for 
improved membrane protein identification by MS. Altogether, this work affords new 
opportunities and methods for large-scale analysis of extracellular glycoproteins, which 







CHAPTER 1. INTRODUCTION TO MASS SPECTROMETRY-
BASED PROTEOMICS AND GLYCOPROTEOMICS 
1.1 Mass spectrometry-based proteomics 
Proteins are one of the most abundant macromolecules within a cell, comprising 
about 50% of the total dry mass, and play key roles in all cellular processes and 
functions.1 As a result, a comprehensive understanding of cellular biology and all related 
processes require knowledge about protein regulation, interactions, function and 
expression. With the advent of soft ionization sources, especially electrospray ionization 
(ESI)2 and matrix-assisted laser desorption/ionization (MALDI)3, mass spectrometry 
(MS) has become an increasingly powerful tool to investigate bio-macromolecules.4-9 
MS-based proteomics techniques offer a unique opportunity to systematically study 
proteins, which is beyond the reach of conventional biochemical methods.10-11 Classical 
antibody-based protein identification methods depend entirely on the availability and 
quality of antibodies. In addition, antibodies are expensive and the experimental 
procedures are typically time-consuming, labor-intensive, and relatively low-throughput. 
Alternatively, MS-based techniques can assist in the confident global identification and 
quantification of proteins without the use of antibodies, due to their high-throughput 
nature.12-14 
Many initial protein studies analyzed selected purified proteins to investigate their 
structure, function or interactions. Now, there is greater interest in comprehensively 
studying all proteins, or the proteome, of a biological sample. Understanding the whole 
 1 
proteome and its structure, function and dynamics has been a central focus of protein 
biology.15 Protein abundances range from several copies to millions of copies per cell, 
and are extremely dynamic in response to internal and external stimuli, which makes their 
comprehensive analysis quite complex.16 MS-based methods provide a platform to 
perform comprehensive protein analysis, through three main approaches: top-down, 
middle-down and bottom-up proteomics. 
1.1.1 Top-down proteomics 
Top-down proteomics approaches analyze intact proteins with mass spectrometry, 
in hopes of gaining complete protein characterization. Protein ions are fragmented in the 
gas phase, and both intact parent and fragment masses are used to determine protein 
sequences.17 Complete coverage at both the intact and fragment ion levels is ideal for 
comprehensive analysis, often times resulting in higher sequence coverage compared to 
bottom-up proteomics.18-19 In theory, analyzing intact proteins makes the entire sequence 
available, thereby enabling the identification of specific protein isoforms and potentially 
improving protein quantification, since protein abundances are used instead of individual 
peptides.20-22 However, there are still technical challenges in this field, including the lack 
of effective fractionation methods for intact protein separation that are compatible with 
MS/MS analysis.23  
1.1.2 Middle-down proteomics 
Between analyzing intact proteins with top-down workflows and smaller peptides 
with bottom-up workflows exists an approach that exploits strengths from both methods 
into middle-down proteomics. With this approach, proteins are digested into medium-
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sized peptides (3 – 15 kDa) which provide more complete sequence information than 
bottom-up methods, and can be more easily fractionated prior to MS analysis by many 
common liquid chromatography (LC) techniques, compared to top-down methods.24 
Here, longer peptides are more likely to have unique sequences and correlate more 
specifically to protein isoforms, compared to bottom-up methods. Since the most 
commonly used protease, trypsin, generates shorter peptides (0.5 – 3 kDa), alternate 
proteases such as Lys-C, Asp-N, Arg-C, or Glu-C must be employed to generate these 
longer peptides.25-27 Middle-down techniques have been successfully applied to a variety 
of protein studies, including histones, polyubiquitin chains and ribosomal proteins.28-31 
However, middle-down proteomics is still less widespread than top-down or bottom-up 
approaches.29 
1.1.3 Bottom-up proteomics 
Bottom-up proteomics, also called ‘shotgun proteomics,’ is the most common 
technique for global protein analysis. These methods rely on protein digestion to generate 
thousands of peptides which are subsequently separated via LC before analysis with 
tandem mass spectrometry (MS/MS).32 Large-scale data analysis involves database 
searching to match acquired tandem mass spectra (MS2) with theoretical spectra and 
determine the corresponding amino acid sequence of the peptide.33-35 Protein 
characterization is subsequently based on peptides identified in the sample.36 Contrary to 
top-down proteomics, fractionation of peptides before MS analysis is relatively easy to 
attain. Due to sample complexity, often times multidimensional LC is employed, to 
obtain ideal separation before analysis with MS.32 
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Depending on the protease used, peptide identifications are somewhat limited 
based on the frequency of cleavage sites within a protein sequence, and the corresponding 
bias of mass spectrometry for relatively short peptides (about 10-20 amino acids in 
length). Trypsin has become the gold standard for large-scale digestion, which 
specifically cleaves at the C-termini of lysine and arginine residues and generates 
peptides within the preferred mass range and with a basic residue at the C-termini. This 
approach has been widely successful for large scale proteome analysis, and is at the core 
of proteomics achievements.32, 37-38 Currently, bottom-up proteomics is the main mode of 
comprehensive MS-based proteome analysis, and is the approach used in this thesis work. 
1.1.4 Quantitative proteomics 
Another main focus of large-scale protein analysis is quantification of the 
proteome. Many studies are interested in protein expression changes in response to a 
stimulus, i.e. drug treatment, pathway inhibition, altered growth conditions, etc. MS-
based methods are not inherently quantitative, due to many variables including sample 
handling, varying ionization efficiency between peptides, and differing retention on 
chromatographic columns.39 However, these methods can be coupled with isotope 
labeling to obtain relative protein abundances. Peptides with the same chemical 
composition, only differing by isotopes at specific positions, are expected to behave the 
same way during chromatographic separation and mass spectrometric analysis. 
Therefore, the peptides will have the same retention time, but can be differentiated 
through extracted ion chromatograms based on their mass-to-charge (m/z) ratios.12 
1.1.4.1 Metabolic isotope labeling 
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Isotopes can be incorporated into media during cell growth with individual 
elements (15N) or amino acids (Leu, Arg, Lys, Tyr) containing 13C and/or 15N.40 For 
example, stable isotope labeling with amino acids in cell culture (SILAC) incorporates 
heavy lysine and arginine residues into proteins, which is particularly useful for labeling 
tryptic digestion peptides.39, 41 In traditional SILAC studies, two cell culture flasks are 
used: one culture is labeled with ‘heavy’ amino acids and typically treated with a 
stimulus, while the other culture is labeled with normal (or ‘light’) amino acids and 
grown under standard conditions. For these approaches, heavy and light peptide pairs in 
the full mass spectrum are compared to determine the relative abundance ratio for each 
peptide, which is then inferred to determine protein abundance changes.12 These methods 
are limited to cell culture and animal models, and cannot be applied to tissue or blood 
samples. 
1.1.4.2 Chemical isotope labeling 
Chemical derivatization is also employed to introduce isotopes by targeting specific 
functional groups within peptides. Tandem mass tags (TMT) and isobaric tags for relative 
and absolute quantification (iTRAQ) labeling methods both target free amines. Briefly, 
these isobaric tags react with free amines in peptides, resulting in identical mass tags on 
each peptide and identical behavior during chromatographic separation. When peptides 
are fragmented for MS/MS, these isobaric tags produce fragments with different masses, 
which are then compared to obtain the relative abundance changes of the peptide. TMT 
and iTRAQ are both multiplexed methods, capable of quantifying multiple samples at 
once: iTRAQ offers 4 or 8 plex, and TMT offers 2, 6 or 10 plex kits.42-43 Multiplexed 
techniques have advantages compared to duplex techniques since they can 
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simultaneously quantify protein expression in up to 10 samples, which is particularly 
useful when quantifying proteins in many samples, or at many time points of a reaction or 
drug treatment.  
Another common chemical isotope labeling method uses isotope-coded affinity 
tags (ICAT), which contain a biotin handle, and label free cysteines within proteins. Two 
protein samples can be quantified simultaneously: one is labeled with a heavy isotope tag, 
and the other with a light tag. After digestion, isotopically labeled peptides are separated 
with avidin affinity chromatography and analyzed with LC-MS/MS. Similar to SILAC, 
heavy and light peptide pairs are quantified based on their relative abundances in the full 
mass spectrum.44-45  
1.2 Glycoproteomics 
Protein modifications are essential in biological systems and involved in nearly 
every cellular event.46-50 There has been great interest in the comprehensive and 
quantitative analysis of modified proteins to obtain a better understanding of protein 
functions and disease mechanisms, which could lead to the discovery of effective 
biomarkers and drug targets.51-53 Although MS-based proteomics has been applied to 
globally identify modified proteins, pinpoint the modification sites, and quantify their 
abundance changes54-58, it is still extraordinarily challenging to achieve these goals in 
complex biological samples for multiple reasons.59-60  
Protein N-glycosylation is one of the most common and important modifications; it 
frequently initiates cell signal transduction and regulates cell-cell communication and 
cell-matrix interactions.61-62 Based on predictions and computational results, about half of 
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all mammalian proteins are glycosylated at any given time.63 During this modification, a 
sugar chain, or glycan, is attached to a protein through either asparagine (N-
glycosylation), serine/threonine (O-glycosylation), or tryptophan (C-glycosylation) and is 
further modified by a variety of enzymes. The work presented here focuses only on N-
glycosylation, which occurs on the consensus motif N-X-S/T, where X is any amino acid 
except proline.64 This is a non-template driven process, which thereby generates a 
complex variety of glycans. Glycosylation often regulates protein folding, stability and 
trafficking, and is also required for many cellular processes, including extracellular 
interactions and immune response.65-66 Aberrant glycosylation is often correlated with 
human diseases including cancer and infectious diseases.53, 67-68 Due to the critical 
importance, frequency and biological implications of glycosylation, there has been 
increased focus on global analysis of protein glycosylation. 
1.2.1 Extracellular glycoproteins 
Extracellular proteins play critical roles in cellular interactions, and the vast 
majority, if not all, are glycosylated. Glycoproteins on the cell surface and in the 
secretome dictate extracellular interactions, cell signaling and immune response, and also 
reflect the disease and developmental status of the cell.69-70 They serve as excellent 
therapeutic targets due to their easy accessibility by small molecules and 
macromolecules.71-72 The majority of FDA approved drugs target membrane or secreted 
proteins.73-74 These glycoproteins also serve as a promising non-invasive source of 
diagnostic biomarkers, since secreted proteins can be found in plasma/blood samples and 
other bodily fluids which are easily accessed for diagnosis and monitoring purposes.75 
Several secreted glycoprotein biomarkers have been verified by the FDA, including 
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prostate-specific antigen (PSA) for prostate cancer, CA125 for ovarian cancer, and 
HER2/NEU for breast cancer.76-77 Comprehensive analysis of these extracellular 
glycoproteins will have significant impacts in biomedical and disease research.77 
However, comprehensive identification of cell surface glycoproteins is even more 
challenging compared to intracellular proteins. It requires specific separation prior to MS, 
which magnifies the difficulties associated with modified proteins mentioned above. 
1.2.2 Difficulties with analysis 
Modified proteins are present at much lower abundance within a cell, compared to 
many non-modified proteins. Previous studies have shown that enzymes responsible for 
glycosylation and other post-translational modifications tend to have less than 500 copies 
per cell. Contrarily, proteins involved in protein synthesis (folding, translation, etc.) are 
present at much higher abundances, greater than 100,000 copies per cell.78 When MS 
analysis is performed on complex biological samples containing low and high abundance 
proteins, low abundance glycoproteins are masked by highly abundant proteins, and are 
rarely detected.79 For this reason, the effective and comprehensive identification of 
glycoproteins requires enrichment methods capable of separating glycoproteins from 
non-glycosylated proteins.  
 Glycosylation is a non-template driven process, resulting in a hypothetically 
infinite variety of glycan structures. As such, the structure of a glycan at a specific site 
can vary greatly for the same protein. Furthermore, the number of glycosylation sites 
occupied within a protein also differs. This micro- and macro-heterogeneity makes MS-
based global analysis of glycoproteins more challenging, since the glycan mass tag and 
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resulting shift are largely unknown.80 Successful enrichment is difficult due to glycan 
structure variability.81 Several enrichment methods are discussed below, but each has 
disadvantages that hinder comprehensive glycoprotein analysis. 
 Analyzing extracellular glycoproteins specifically, which is the focus of this 
thesis, further complicates enrichment and identification methods. The majority of 
extracellular proteins are predicted to be glycosylated, yet their low abundance and 
difficulties in separation prevent their comprehensive analysis. In addition to extracellular 
glycoproteins being masked by higher abundance non-modified proteins during MS 
analysis, they also are masked by intracellular glycoproteins. Therefore, there is a 
demand for effective methods that specifically target cell surface and extracellular 
glycoproteins for MS-based proteomics.  
1.2.3 Current methods 
Due to the growing recognition of glycoprotein significance in disease and 
biological processes, several enrichment methods have been developed for large-scale 
glycoprotein analysis. In general, enrichment methods take advantage of the common 
properties of glycans, including their many hydroxyl groups and hydrophilicity. While 
considerable progress has been made in large-scale glycoprotein analysis, it is still 
extremely challenging to attain complete glycoproteome analysis. The most common 
techniques utilize hydrophilic interaction liquid chromatography, lectins, boronic acid or 
hydrazide chemistry for enrichment, but the majority are not appropriate for extracellular 
glycoprotein enrichment. 
1.2.3.1 Hydrophilic interaction liquid chromatography 
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Although glycan structures are very heterogeneous, all glycopeptides contain 
hydrophilic carbohydrate groups, which are exploited for glycopeptide enrichment with 
hydrophilic interaction liquid chromatography (HILIC).82-83 In general, HILIC is used to 
separate hydrophilic glycopeptides from more hydrophobic peptides. However, this 
technique lacks specificity for glycopeptides; many non-glycosylated peptides may be 
separated along with glycopeptides, and as a result this method is not ideal for 
glycopeptide enrichment in complex biological samples. Several improvements have 
been made to HILIC enrichment methods, including using ion-pairing with trifluoroacetic 
acid (TFA) to increase the hydrophilicty of glycopeptides and enhance enrichment.84-85 
1.2.3.2 Lectin enrichment 
The most common method employed for glycoprotein/peptide separation uses 
lectins, which are glycan-binding proteins. Hundreds of lectins exist, and each lectin has 
inherent specificity for one or several glycans. As a result, lectin enrichment methods are 
not comprehensive, since there is no general lectin capable of binding to all glycans. 
While each lectin is highly specific for a particular carbohydrate moiety, the binding 
affinities of lectin-carbohydrate interactions are relatively low (low micromolar to 
millimolar range), which is another drawback of this method.86-88 With low binding 
affinities, there are fewer options for washing away non-specifically bound 
peptides/proteins. Nevertheless, lectins have been used to successfully analyze 
glycoproteins in a variety of complex samples.89-91 However, lectin-based methods on 
their own are not applicable for extracellular glycoprotein enrichment. 
1.2.3.3 Boronic acid enrichment 
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Boronic acid chemistry has been applied for comprehensive glycoprotein 
enrichment. This technique is universal and can enrich all glycoproteins containing 
glycans with cis-diols.92-93 Boronic acid forms reversible covalent interactions with cis-
diols in glycans under basic conditions, and non-specifically bound glycoproteins can be 
washed away before eluting glycoproteins from boronic acid under acidic conditions.94-95 
This approach has been applied to enrich glycoproteins in serum and saliva.96-97 Our 
group has implemented boronic acid conjugated magnetic beads for glycoprotein 
enrichment, which has proven to be highly effective in yeast.98 Boronic acid enrichment 
serves as a promising avenue for comprehensive glycoprotein analysis; however these 
methods are unable to specifically enrich cell surface glycoproteins. 
1.2.3.4 Hydrazide chemistry based enrichment 
Hydrazide chemistry can be exploited for glycoprotein enrichment because it 
readily reacts with oxidized cis-diols in glycans. The first application of this utilized 
hydrazide attached to a solid support to capture oxidized glycoproteins from human 
serum, followed by proteolysis, removal of non-glycosylated peptides, and release using 
peptide N-glycosidase F (PNGase F).99 A variation of this method performs the oxidation 
at the peptide level.100 These methods have been applied to a variety of samples, 
including human plasma, islets, platelets, and saliva.101-106 The oxidation conditions were 
then further optimized for compatibility with live-cell labeling: cell surface glycoproteins 
were labeled with biocytin hydrazide, digested and subsequently enriched with 
streptavidin beads.107 This method has been widely applied for the specific identification 
of surface N-glycoproteins. However, the oxidation of carbohydrates is performed under 
relatively harsh conditions, which may act as an external stimulus for cells and cause side 
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reactions within proteins, which is the main drawback of this method.108 Therefore, there 
is a need for an effective and specific method to enrich surface and extracellular 
glycoproteins that can be performed under mild conditions. 
1.3 Goals of thesis 
The overall goal of this thesis is to develop novel MS-based methods for global and 
accurate analysis of cell surface and extracellular glycoproteins. Glycosylation is one of 
the most common protein modifications in cells, and glycoproteins are critical for many 
cellular activities, especially extracellular interactions. Cell surface and extracellular 
glycoproteins are of particular interest because they frequently represent the cellular 
status, and serve as a promising source of biomarkers for disease progression and drug 
targets. Despite the prevalence and importance of protein glycosylation, it is extremely 
challenging to globally identify glycoproteins, due to the low abundance of many 
glycoproteins, heterogeneity of glycans, and complexity of biological samples. It is even 
more difficult to specifically characterize glycoproteins located only on the cell surface 
and in the secretome. The work described here provides novel MS-based methods to 
comprehensively analyze extracellular glycoproteins. Effective methods to investigate 
surface and secretory glycoproteins on a large scale enable a better understanding of 
glycoprotein function and the molecular mechanisms of disease. The methods presented 
in this dissertation provide the foundation for the future discovery of specific 
glycoproteins as drug targets and biomarkers for disease.  
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Glycosylation is one of the most common and critical protein modifications in 
cells; it has been estimated that about 50% of proteins expressed in a cell are 
glycosylated.1  Additionally, nearly all extracellular proteins are glycosylated, including 
cell surface and membrane proteins.  These extracellular glycoproteins play crucial roles 
in cell-cell interactions and immune response.2-3  Abnormal glycosylation is correlated 
with the development of disease, including cancer and Alzheimers.4-5  Extracellular 
glycoproteins often represent the diseased or developmental status of the cell, and 
therefore are a promising source of non-invasive biomarkers.6  Furthermore, cell surface 
glycoproteins are commonly used as therapeutic targets; the majority of FDA approved 
drugs target surface proteins.7-8  Therefore, there is great interest in comprehensively 
analyzing cell surface glycoproteins, but there is a lack of effective methods.  As 
described in Chapter 1.2.1, extracellular glycoprotein analysis is extremely challenging, 
and requires effective enrichment from non-modified and intracellular proteins. 
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Several years ago a very elegant cell surface capturing method was reported for 
cell surface glycoprotein analysis.9 Glycoproteins on living cells were oxidized, bound to 
biotin through a bifunctional linker molecule, biocytin hydrazide, and enriched by avidin 
for MS analysis. However, the oxidation reaction conditions are not under physiological 
conditions and therefore can act as an external stimulus to cells. Effective methods will 
profoundly advance the analysis of cell surface glycoproteins and provide insight into 
glycoprotein function. 
In this work we have developed an effective MS-based method to identify cell 
surface glycoproteins comprehensively and site-specifically. A sugar analog containing a 
biologically inert but chemically functional azido group was fed to cells to label cell 
surface glycoproteins according to a previous method.10 Surface glycoproteins containing 
the functional group were subsequently bound to biotin through copper-free click 
chemistry under mild physiological conditions. Further separation and enrichment by 
exploiting the strong interaction between biotin and avidin allowed the global analysis of 
cell surface glycoproteins. 
2.2 Experimental Methods 
2.2.1 Cell culture and surface glycoprotein labeling 
HEK 293T cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10 % fetal bovine serum (FBS). Once cells reached 10 % confluency, medium 
was changed to DMEM containing 10 % FBS and 50 µM N-azidoacetylgalactosamine 
(GalNAz). Cells were incubated for 3 days until confluency was ~80%. After metabolic 
labeling, cells were washed with phosphate buffered saline (PBS) two times and 100 µM 
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dibenzocyclooctyne (DBCO)-sulfo-biotin in PBS was added into the culture flasks. Cells 
were incubated for one hour with gentle agitation at 4 ºC and then harvested by scraping 
in PBS and centrifugation at 300 g for 5 minutes. The supernatant was discarded and the 
cell pellet containing about 4x107 cells was washed twice with PBS containing 10 mM 
dithiothreitol (DTT). 
2.2.2 Cell lysis and membrane protein extraction 
The cell pellet was incubated in a buffer containing 150 mM NaCl, 50 mM 2-[4-
(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) (pH=7.4), 25 ug/mL 
digitonin, and Roche protease inhibitor (1 tablet per 10 mL) with end-over-end rotation 
for 10 minutes at 4°C. After incubation, samples were centrifuged at 2,000 g for 10 
minutes. Cell pellets were washed with the buffer twice and subsequently lysed with the 
MiniBeadbeater (Biospec) in a buffer containing 10 mM HEPES, 1.5 mM MgCl2 and 10 
mM KCl. The resulting solutions were centrifuged at 2,500 g for 10 minutes, and the 
supernatant was collected and centrifuged at 16,000 g for 30 minutes. The membrane rich 
pellet was collected and washed two times with the lysis buffer. The pellet was further 
incubated in 0.1 M sodium carbonate solution containing 1 mM 
ethylenediaminetetraacetic acid (EDTA) on ice for 30 minutes, followed by 
centrifugation at 16,000 g for 15 minutes. Sodium carbonate incubations and subsequent 
centrifugations were repeated once. The membrane rich pellets were incubated with 
shaking in a buffer containing 4 M urea, 100 mM NaCl, 10 mM HEPES, and 1 mM 
EDTA for 30 minutes at room temperature, and then samples were centrifuged at 16,000 
g for 15 minutes. The urea buffer wash was repeated once. Solubilization buffer 
 25 
containing 100 mM PBS and 1 % NP-40 was added to cell pellets and incubated end-
over-end overnight at room temperature. 
2.2.3 Glycopeptide preparation and enrichment 
Solubilized samples were centrifuged at 16,000 g for 15 minutes and supernatants 
were collected. Disulfide bonds within proteins were reduced with 5 mM DTT (56 °C, 25 
minutes) and subsequently alkylated with 14 mM iodoacetamide (room temperature, 30 
minutes in the dark). After reduction and alkylation, proteins were purified with the 
methanol chloroform protein precipitation method 11. Four volumes of methanol, one 
volume of chloroform and three volumes of water were added to one volume of the 
protein sample, and the mixture was vortexed. The sample was centrifuged at 5,000 g for 
20 minutes. The proteins remained at the phase boundary between the methanol and 
chloroform layers. The methanol layer above the sample was removed. Four volumes of 
methanol were added, and the mixture was vortexed again. The sample was centrifuged 
again at 5,000 g for 15 minutes. The supernatant was removed without disturbing the 
pellet, and the pellet was dried. 
The resulting ~2 mg protein samples were digested overnight at a protein:trypsin 
ratio of ~100:1 in 2 mL of  buffer containing 50 mM HEPES (pH=8.5), 0.1 M urea, and 
5% ACN. The next day, the digestion was quenched by the addition of trifluoroacetic 
acid (TFA) to a final concentration of 0.1% and digested peptides were purified with a 
200 mg Sep-Pak tC18 cartridge. Purified samples were dried and enriched with 200 µL of 
NeutrAvidin bead slurry end-over-end for 30 minutes at 37 °C. After enrichment, the 
peptide sample was transferred to a spin column and beads were washed ten times with 
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400 µL PBS and once with water. Peptides were eluted from the beads twice by two 
minute incubations with 200 µL of 8 M guanidine (pH=1.5) at 56 °C. Combined eluates 
were purified on a 50 mg Sep-Pak tC18 cartridge. Enriched peptides were dried 
thoroughly before enzymatic deglycosylation with 8 units of peptide-N-glycosidase F 
(PNGase F, Sigma-Aldrich) in 40 µL of buffer containing 40 mM NH4HCO3 in heavy-
oxygen water (H218O) for three hours at 37 °C. The deglycosylation reaction was 
quenched with formic acid (FA) and purified with the stage tip method. Proteins were 
eluted into three samples using 20%, 50% and 80% ACN each containing 1% HOAc. 
2.2.4 LC-MS/MS analysis 
Purified samples were dried and resuspended in a solvent containing 5% ACN 
and 4% FA, and 4 μL were loaded onto a C18-packed microcapillary column (Magic 
C18AQ, 5 μm, 200 Å, 100 μm x 16 cm) using a WPS-3000TPL RS autosampler 
(Thermostatted Pulled Loop Rapid Separation Nano/Capillary Autosampler, Dionex). 
Peptides were separated by reversed-phase chromatography using an UltiMate 3000 
binary pump with a 110 minute gradient that varied for three samples. The first sample 
had a gradient of 4-25% ACN (0.125% FA), the second sample’s gradient was 10-38% 
ACN (0.125% FA) and the third sample had a gradient of 15-50% ACN (0.125% FA). 
Samples were detected in a hybrid dual-cell quadrupole linear ion trap – Orbitrap mass 
spectrometer (LTQ Orbitrap Elite, ThermoFisher) using a data-dependent Top 20 
method. Each cycle included one full MS scan (resolution: 60,000) in the Orbitrap at the 
Automatic Gain Control (AGC) target of 1 million, followed by up to 20 MS/MS of the 
most intense ions in the LTQ. Selected ions were excluded from being further sequenced 
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for 90 seconds. Ions with a single or unassigned charge were not fragmented. Maximum 
ion accumulation times were 1000 ms for each full MS scan and 50 ms for MS/MS scans. 
2.2.5 Database searches and filtering 
The raw files recorded by MS were converted into mzXML format. Precursors for 
MS/MS fragmentation were checked for incorrect monoisotopic peak assignments while 
refining precursor ion mass measurements. The SEQUEST algorithm 12 (version 28) was 
used to search and match all MS/MS spectra against a database encompassing sequences 
of all proteins in the Uniprot Human (Homo sapiens) Database containing common 
contaminants such as keratins. Each protein sequence was listed in both forward and 
reversed orientations to estimate the false discovery rate (FDR) of glycopeptide 
identification.13-14 A 20 ppm precursor mass tolerance and 1.0 Da product ion mass 
tolerance were used in the database search. Other selected parameters were fully tryptic 
digestion, up to two missed cleavages, variable modifications including oxidation of 
methionine (+15.9949) and 18O tag of Asn (+2.9883), and fixed modifications including 
carbamidomethylation of cysteine (+57.0214). 
In order to evaluate and further control FDRs of glycopeptide identification, the 
target-decoy method was employed.13-14 Linear discriminant analysis (LDA) was utilized 
to distinguish correct and incorrect peptide identifications using numerous parameters 
including XCorr, ΔCn, and precursor mass error.15 Separate linear discriminant models 
were trained for each raw file using forward and reversed peptide sequences to provide 
positive and negative training data. This approach is similar to other methods in the 
literature.16-17 After scoring, peptides less than six amino acids in length were discarded 
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and peptide spectral matches were filtered to a less than 1% FDR based on the number of 
decoy sequences in the final data set. The dataset was restricted to glycopeptides when 
determining FDRs. 
2.2.6 Glycosylation site localization 
To localize glycosylation sites and obtain a level of confidence corresponding to 
the identification, we applied a probabilistic algorithm that considers all potential 
glycosylation sites on a peptide and uses the presence or absence of experimental 
fragment ions unique to each to obtain a ModScore.18 The ModScore, which is similar to 
Ascore, indicates the likelihood that the best site match is correct when compared with 
the next best match.18 If only one glycosylation site is possible, a value of 1000 is 
assigned to the site. We considered sites with a score ≥19 (P≤ 0.01) to be confidently 
localized. 
2.3 Results and Discussion 
2.3.1 Glycopeptide labeling and enrichment 
Sugar analogs have frequently been used to discover glycotransferase inhibitors.19 
Some sugar analogs can be used by glycosyltransferases to modify glycans within 
mammalian proteins. By taking advantage of this discovery, scientists have extensively 
investigated culturing cells with sugar analogs bearing various functional groups, 
including azido, alkyl and aldehyde groups.10, 20-22 The azido functional group in the 
sugar analog serves as a chemical handle for the click chemistry reaction which will 
provide further insight into protein function and cellular activities. 
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In recent years, metabolic labeling has been employed for in vivo imaging 
experiments and valuable information has been obtained regarding the location of the 
sugar analogs and their relative abundance changes based on the fluorescence signal and 
corresponding intensity changes.21, 23 In previous studies, GalNAz has been used in 
mammalian cells to modify proteins, resulting in azido-containing glycoproteins.24 In this 
experiment, GalNAz was added into DMEM and incubated with HEK 293T cells in order 
to metabolically label glycoproteins.  
Cell surface glycoproteins with the functional azido group were selectively bound 
to biotin through copper-free click chemistry, as shown in Figure 2.1. The copper-free 
click chemistry reaction between DBCO and the functional azido group is very specific, 
rapid and efficient.25-26 More importantly, the reaction can occur under physiological 
conditions, without toxic heavy metal ions (Cu(I) and Cu(II)) that are frequently used as a 
catalyst in the traditional copper-catalyzed azide-alkyne cycloaddition (CuAAC), which 
allows surface glycoproteins on living cells to be tagged and minimizes external 
stimuli.27   After metabolic labeling and surface glycoprotein tagging, cells were lysed 
and proteins were extracted and digested. Based on the strong and specific interaction 
between biotin and avidin, glycopeptides tagged with biotin were selectively enriched by 
incubation with NeutrAvidin conjugated agarose beads. After incubation, the beads were 
washed to remove non-biotinylated peptides, and enriched glycopeptides were 
subsequently eluted from the beads. 
Enriched glycopeptides were dried for at least 24 hours in a vacuum concentrator 
and then treated with PNGase F in heavy-oxygen water. This enzyme cleaves N-glycans 
and converts asparagine (Asn) to aspartic acid (Asp) in the process. The deamination of 
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Asn can also occur in vivo and during sample preparation. By performing this enzymatic 
deglycosylation in heavy-oxygen water, newly formed Asp is labeled with 18O, which 
helps distinguish bona fide glycosylation sites from those caused by non-enzymatic 
deamination.28-29 As a result, N-glycopeptides and their corresponding glycosylation sites 
were confidently identified and localized. 
 
Figure 2.1. Principle of the cell surface glycoprotein enrichment method including 
(A) the metabolic labeling and click chemistry reaction, and (B) glycopeptide 
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2.3.2  Glycopeptide identification and site localization 
Using this novel strategy, 144 unique N-glycosylated peptides were identified.  
Figure 2.2 shows example tandem mass spectra of three identified N-glycopeptides, 
EN#TSDPSLVIAFGR, GHTLTLN#FTR, and YSVQLMSFVYN#LSDTHLFPN#ASSK 
(# denotes the glycosylation site) from lysosome-associated membrane glycoprotein 1 
(LAMP1), which is a single-pass type I membrane protein. It presents carbohydrate 
ligands to selectins and is involved in tumor cell metastasis.30 These peptides were 
confidently identified with XCorr values of 4.11, 2.45, and 4.50, respectively. The high 
mass accuracy of each identification is represented by their ppm values of 0.84, 0.14 and 
-0.16. The full sequence of this protein is shown in Figure 2.2D, with identified peptides 
highlighted. Corresponding glycosylation sites were confidently localized at N84, N103, 
N121 and N130, with ModScore values of 1000 for each. Additionally, all sites contain 
the consensus motif Asn-X-Ser/Thr, where X is any amino acid residue except proline. 





Figure 2.2. Tandem mass spectra of three peptides from the LAMP1 protein, 
including (A) EN#TSDPSLVIAFGR, (B) GHTLTLN#FTR, and (C) 
YSVQLMSFVYN#LSDTHLFPN#ASSK (# denotes the glycosylation site). The 
complete protein sequence with the highlighted identified peptides is shown in (D). 






























































































































































































  The high resolution and mass accuracy of the Orbitrap mass spectrometer allowed 
for the very confident N-glycopeptide identifications. The mass accuracy distribution of 
all identified N-glycopeptides is displayed in Figure 2.3A. Clearly, the vast majority of 
identified glycopeptides have a mass accuracy of less than 3 ppm. The mass accuracy 
results show the high confidence level associated with glycopeptide identifications. This 
is further confirmed by the XCorr values, which are shown in Figure 2.3B. Most of the 
XCorr values are greater than 3, and only several of them are less than 2. We manually 
checked glycopeptide identifications with relatively low XCorr values, and all of them 
were relatively short peptides whose fragments matched very well with corresponding 
theoretical spectra. The low XCorr values assigned to short peptides are due to the fact 
that the peptide matches are normally biased for longer peptides, i.e., higher XCorr 




Figure 2.3. Distribution of (A) ppm and (B) XCorr values assigned for each 
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Figure 2.4. Number of N-glycosylation sites identified in (A) peptides and (B) 





































Overall, 152 sites were identified on 110 cell surface glycoproteins in HEK 293T 
cells. The major advantage of the current method is that cell surface glycoproteins 
containing the azido group can be labeled under mild physiological conditions.  The 
limitations of the current method include that the metabolic labeling method is not 
suitable for clinical tissue samples, but it can be employed for cultured cells and also 
model animals such as mice and zebrafish.23, 32 In addition, this method can only be used 
to identify N-glycopeptides containing GalNAc, but even with this limitation, more than 
150 unique glycosylation sites were identified in over one hundred cell surface proteins. 
The number of glycosylated proteins identified with the current method is comparable to 
previous results, in which 110 glycoproteins in Jurkat T-lymphocyte cells were identified 
with the cell surface-capturing method.9 
The majority of N-glycopeptides identified (95%) contained only one 
glycosylation site. Figure 2.4A shows the distribution of glycosylation sites in peptides; 
very few (6 peptides) have two sites, and only one contains three N-glycosylation sites. 
Similarly, most proteins (72%) are singly glycosylated, and 21% of them contain two N-
glycosylation sites (Figure 2.4B). The protein that contains five glycosylation sites was 
identified as nicastrin (NCSTN), which is an essential subunit of the gamma-secretase 
complex that is widely expressed in many different tissues.33 
Based on the same probability principle of Ascore, ModScore evaluates the 
confidence associated with each site localization.18, 34-35 A value greater than 19 indicates 
a higher than 99% confidence level associated with the site localization, and a score 
greater than 13 corresponds to a higher than 95% confidence level. Among all the 
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identified sites, 87%  have a ModScore larger than 19, and only a very small portion of 
them (8%) have a ModScore less than 13, as shown in Figure 2.4C. 
2.3.3 Cell surface N-glycoprotein clustering 
All glycoproteins identified in this work were clustered using the Database for 
Annotation, Visualization, and Integrated Discovery (DAVID).36 Membrane proteins 
were highly enriched with a P value of 1.37E-22. Of the 110 total proteins identified, 104 
were categorized as membrane proteins. Six proteins were not defined as membrane 
proteins in the DAVID analysis, which could be due to incorrect annotations of these 
proteins, contamination and/or experimental errors. Alternatively, they could be non-
membrane proteins that are located on the cell surface through an anchor such as 
glycophosphatidylinositol (GPI) or other modified lipid groups.  
All identified glycoproteins were categorized according to biological process 
using DAVID. The biological processes with the highest enrichment include cell 
adhesion, cell motion, structure morphogenesis, transport, interspecies interaction, 
positive immune regulation, cell projection organization, stimulus response and cell 
recognition (Figure 2.5A), all of which are consistent with the biological processes 
associated with cell surface proteins. Glycoproteins were also clustered based on 
molecular function, and the protein functions that were most highly enriched include 
signal transducer activity, transporter activity, and carbohydrate binding, as shown in 




Figure 2.5. Clustering of glycoproteins based on (A) biological process and (B) 
molecular function. 
 
2.3.4 N-glycosylation sites on cell surface transporters 
Membrane transporter proteins compose a large group of cell surface proteins and 
they regulate the input and output of many molecules and ions. About 10% of human 
genes are transporter-related, which is corresponds well with the biological significance 
of transporters and their roles in cell homeostasis.38 These membrane transporter proteins 
can serve as potential biomarkers and therapeutic targets. There were 10 transporter 
















































































































































































Table 2.1. N-glycosylation sites in transporter proteins identified in the current cell surface experiment (# denotes 
glycosylation site). 
Protein Site ModScore Peptide XCorr ppm Annotation 
SLC1A4 201 206 
1000 
1000 VVTQN#SSSGN#VTHEK 3.4 -0.45 
Neutral amino acid transporter; transports 
alanine, serine, cysteine and threonine 
SLC1A5 212 1000 SYSTTYEERN#ITGTR 3.2 -0.11 Neutral amino acid transporter; accepts all neutral amino acids 
SLC2A1 45 1000 VIEEFYN#QTWVHR 3.6 0.38 Facilitated glucose transporter member 
SLC30A6 352 17.0 DDWIRPALLSGPVAANVLN#FSDHHVIPMPLLK 3.0 -0.94 Zinc transporter 
SLC39A10 339 106.2 DLNEDDHHHECLN#VTQLLK 3.7 -0.08 Zinc transporter 
SLC39A6 
266 23.6 NTNENPQECFN#ASK 2.8 0.65 
Zinc-influx transporter 283 24.6 LLTSHGMGIQVPLN#ATEFNYLCPAIINQIDAR 5.0 -0.55 
67 24.4 YGEN#NSLSVEGFRK 3.8 0.23 
SLC3A2 
365 1000 DASSFLAEWQN#ITK 3.1 0.19 Involved in sodium-independent neutral amino 
acid transport including phenylalanine, 
tyrosine, leucine, arginine and tryptophan 
381 181.2 LLIAGTN#SSDLQQILSLLESNK 5.3 -0.46 
424 59.3 SLVTQYLN#ATGNR 3.5 -0.75 
SLC44A2 187 1000 GVLMVGN#ETTYEDGHGSRK 3.5 3.24 Choline transporter-like protein 417 84.6 TCNPETFPSSN#ESR 2.5 1.76 
SLC4A7 776 13.4 LTSYSCVCTEPPNPSN#ETLAQWK 3.8 3.43 Sodium bicarbonate cotransporter 
SLC6A15 187 1000 N#ASHTFVEPECEQSSATTYYWYR 5.0 0.48 
Sodium-dependent neutral amino acid 




The protein solute carrier family 3 member 2 (SLC3A2), also designated as 
cluster of differentiation 98 (CD98), is the 4F2 cell-surface antigen heavy chain and is 
required for the function of light chain amino-acid transporters.39 In this experiment, 
three N-glycopeptides were confidently identified from SLC3A2, i.e. 
DASSFLAEWQN#ITK, LLIAGTN#SSDLQQILSLLESNK and SLVTQYLN#ATGNR 
with corresponding N-glycosylation sites at N365, N381 and N424.  
N-glycosylation may play determinant roles in trafficking these proteins to the 
cell surface since glycosylation has been proven to regulate the classical secretory 
pathway.40 Glycans within proteins can significantly increase the overall hydrophilicity 
and impact protein interactions with other small molecules or macromolecules. 
Reversible glycan binding on these cell surface transporters may also participate in the 
regulation of molecular transport through the cell membrane. 
2.3.5 N-glycosylation sites on cluster of differentiation proteins 
Molecules presented on the cell surface can differentiate and classify the cell type. 
Cluster of differentiation (CD) molecules are a group of cell surface molecules that are 
selected to distinguish cell type. Traditionally these CDs are targets for 
immunophenotyping and often have a wide variety of functions.41 For example, some 
CDs are receptors or ligands and some contribute to cell adhesion. To date, around 450 
CDs have been designated to different types of human cells, among which about 380 are 
surface proteins. In this experiment, 35 N-glycosylation sites were located on 24 CDs in 
HEK 293T cells and some selected sites are listed in Table 2.2. All sites identified in CDs 




Table 2.2. Selected CD proteins identified and their corresponding N-glycosylation sites (# denotes glycosylation site). 
Protein CD Site ModScore Peptide XCorr ppm Annotation 
ATP1B3 CD298 124 1000 N#LTVCPDGALFEQK 3.1 -0.12 Na/K-transporting ATPase subunit beta-3 
BSG CD147 
160 1000 ILLTCSLN#DSATEVTGHR 2.3 0.17 Basigin; participates in the targeting of monocarboxylate transporters to the plasma 
membrane 268 1000 ALMN#GSESR 2.0 -0.11 
CD276 CD276 
104 1000 TALFPDLLAQGN#ASLR 4.0 -0.42 May be involved in regulation of T-cell-
mediated immune response 215 1000 VVLGAN#GTYSCLVR 3.4 0.86 
CD46 CD46 83 1000 GYFYIPPLATHTICDRN#HTWLPVSDDACYR 3.1 1.69 
Membrane cofactor protein; cofactor for 
complement factor I 
CD97 CD97 371 1000 N#VTMGQSSAR 1.4 0.13 Receptor possibly involved in adhesion and signaling after leukocyte activation 
INSR CD220 445 1000 HN#LTITQGK 2.2 0.06 Insulin receptor; receptor tyrosine kinase that mediates the action of insulin 
ITGA1 CD49a 840 1000 FN#VSLTVK 1.7 0.09 Integrin alpha-1; receptor for laminin and collagen 
ITGA2 CD49b 105 68.0 LNLQTSTSIPN#VTEMK 3.5 0.99 
Integrin alpha-2; receptor for laminin, 
collagen, collagen C-propeptides, 
fibronectin and E-cadherin 
ITGA5 CD49e 182 1000 EPLSDPVGTCYLSTDN#FTR 4.2 -1.51 
Integrin alpha-5; receptor for fibronectin 
and fibrinogen 
MCAM CD146 56 1000 CGLSQSQGN#LSHVDWFSVHK 3.5 0.19 
Cell surface glycoprotein MUC18; 
participates in cell adhesion 
 
 
Integrins are cell adhesion receptors that are conserved among species, and play 
critical roles in developmental and pathological processes. The integrin family is heavily 
involved in mediating the attachment of cells to the extracellular matrix and also takes 
part in specialized cell-cell interactions.42 Integrin alpha-1 (ITGA1), designated as 
CD49a, acts as a receptor for laminin and collagen and participates in anchorage-
dependent, negative regulation of epidermal growth factor-stimulated cell growth. 
Integrin alpha-2 (ITGA2), CD49b, is a receptor for laminin, collagen, collagen C-
propeptides, fibronectin and E-cadherin. It is also accountable for adhesion of platelets 
and other cells to collagen, the modulation of collagen and collagenase gene expression, 
and organization of newly synthesized extracellular matrix. Integrin alpha-5 (ITGA5), 
CD49e, is a receptor for fibronectin and fibrinogen. Glycosylation sites were identified 
on each of these three cell surface integrins in HEK 293T cells.  
CD molecules are crucial for classifying cells, but their glycosylation remains 
largely unstudied. Considering the importance of these molecules and protein 
glycosylation on the cell surface, information regarding CD glycosylation can provide 
insight into the functions of these molecules. Cell surface protein glycosylation analysis 
can offer valuable information that will lead to the identification of potential drug targets 
and biomarkers for diseases. 
2.4 Conclusions 
Glycoproteins on the cell surface are essential for a wide range of cellular events, 
and their global analysis is exceptionally challenging. A novel method has been 
developed that integrates metabolic labeling, copper-free click chemistry and mass 
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spectrometry-based proteomics to comprehensively and site-specifically analyze cell 
surface N-glycoproteins. Labeling proteins with the azido functional group allows the 
selective enrichment and separation of cell surface glycoproteins, while the copper-free 
click chemistry reaction tags cell surface glycoproteins with biotin under physiological 
conditions. In this experiment, 152 N-glycosylation sites were identified in 110 cell 
surface proteins in HEK 293T cells by MS. The main functions assigned to identified 
surface N-glycoproteins, including signal transducer, transporter, binding, and catalytic 
activity, are consistent with the documented functions of cell surface proteins. The 
current strategy provides an effective method for large-scale analysis of the cell surface 
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Epithelial cells can transform into mesenchymal cells in a process known as the 
epithelial-mesenchymal transition (EMT). This process is integral for a wide variety of 
necessary physiological processes, including development and healing, as well as 
adaptive processes such as tumor progression and metastasis.1-3 EMT occurs under a 
variety of conditions, and three types of EMT have been proposed. Type 1 EMTs are 
involved in embryo formation and organ development, and do not cause systemic 
invasiveness. Type 2 EMTs are associated with inflammation, such as wound healing and 
tissue regeneration, and type 3 EMTs are involved in tumor cell metastasis and cancer 
progression.4 Despite their differences, cells undergoing EMT appear to have similar 
processes and characteristics. 
Epithelial cells form monolayers that are held together through cell adhesion 
molecules like E-cadherin, and are attached to a matrix through basement membrane 
anchors.5 As cells transition from epithelial to mesenchymal, they lose cell adhesion 
properties and gain motility and invasive properties.4 This mesenchymal phenotype 
allows tumor cells to detach from surrounding cells and enter the circulatory system 
during metastasis.6-7  
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Since its initial discovery in 1995, EMT has been the focus of many developmental 
and disease studies, to attain a better understanding of the underlying signaling 
mechanisms involved in EMT.8-11 There has been great interest in deciphering the 
alternate roles EMT plays in embryonic development and wound healing, compared to 
pathological processes such as fibrosis, and cancer progression.12-14 As a result, many 
transcription factors and genes have been found to play a role in EMT, including Snail1, 
Snail2, Zeb2, and Twist.5, 12, 15-16 Several hallmarks of this transition have been identified, 
for example, E-cadherin is down-regulated as cells lose epithelial properties, and N-
cadherin is up-regulated as they gain mesenchymal properties. Other proteins up-
regulated during EMT are fibronectin, vimentin and laminin.5 However, surface 
glycoproteins have yet to be globally analyzed in the context of EMT. 
A recent review outlines epigenetic and post-translational modifications that play a 
role in EMT, including DNA methylation, histone modifications, hydroxylation, 
phosphorylation, small ubiquitin-like modifier conjugation (SUMOylation) and O-
glycosylation.17 Most of these modifications impact individual proteins involved in EMT, 
for example, phosphorylation and O-GlcNAcylation of SNAIL both regulate EMT. 
Additionally, the SUMOylation of FOXM1 represses miR-200b/c in breast cancer cells, 
and promotes EMT.18 However, global analysis of these modifications during EMT has 
yet to be performed. 
Another study has investigated how aberrant glycosylation through the hexosamine 
biosynthesis pathway (HBP) is induced in EMT. The HBP generates UDP-GlcNAc, 
which is a precursor for O-GlcNAcylation and N-glycosylation. Cell surface glycans 
were found to have increased α2-6 sialylation, poly-LacNAc, and fucosylation, and O-
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GlcNAc was found to be modulated during EMT.17 Glycoproteins on the cell surface 
regulate nearly every cellular activity and are known to be highly involved in cell 
adhesion, motility and invasiveness.19-20 Based on changes in cell properties during EMT, 
surface glycoproteins may also play a critical role in EMT and are predicted to be 
modulated throughout the transition. 
In order to investigate cell surface N-glycoprotein changes throughout EMT, we 
induced EMT in MCF 10A cells with transforming growth factor-β (TGF-β), and paired 
quantitative multiplexed proteomics techniques with our cell surface glycoprotein 
analysis method (described in Chapter 2). Our method integrates metabolic labeling, 
copper-free click chemistry and MS-based proteomics to selectively and site-specifically 
identify surface N-glycoproteins.21 Here, through combination with multiplexed 
proteomics, we systematically quantified cell surface N-glycoproteins throughout EMT. 
Whole proteome changes were also quantitated with HPLC fractionation and TMT 
labeling. Systematic investigation of cell surface glycoproteins will provide insight into 
the molecular mechanisms of EMT. 
3.2 Experimental Methods 
3.2.1 Cell culture and TGF-β treatment 
MCF 10A cells were purchased from ATCC and grown in Mammary Epithelial 
Cell Growth Medium (MEGM, Lonza) containing bovine pituitary extract (BPE), 
hydrocortisone, human epidermal growth factor (hEGF), insulin (from the Lonza MEGM 
BulletKit, CC-3150) and 100 ng/mL cholera toxin. 
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EMT was induced by treatment with 4 ng/mL TGF-β. All cells were labeled with 
100 µM GalNAz for 4 days prior to harvesting. Cells were washed with PBS and media 
was replaced every two days to ensure consistent concentrations of TGF-β and GalNAz. 
Different time points (i.e. 0, 4 and 8 days after treatment) were chosen to investigate cell 
surface glycoproteins throughout EMT. For each time point, when cells were ~90% 
confluent, they were washed with PBS and the copper-free click reaction was performed 
with 100 µM dibenzocyclooctyne (DBCO)-sulfo-biotin in cell stripper, for one hour at 37 
°C. Cells were harvested by scraping and centrifugation at 300 g for 5 minutes, and 
washed with 10 mM dithiothreitol (DTT). 
3.2.2 Lysis, protein digestion and NeutrAvidin enrichment 
Cells were resuspended in digitonin buffer (150 mM NaCl, 25 µg/mL digitonin, 
50 mM HEPES, pH=7.9, and protease inhibitor cocktail (1 tablet per 10 mL buffer, 
Roche)) and incubated 10 minutes at 4 °C with end-over-end rotation. Samples were 
centrifuged at 2000 g for 10 minutes and supernatants were discarded. Cell pellets were 
resuspended in buffer (150 mM NaCl, 0.5% sodium deoxycholate (SDC), 20 units/mL 
benzonase, 50 mM HEPES, pH=7.9, and protease inhibitor cocktail (same concentration 
as above)) and incubated 45 minutes at 4 °C with end-over-end rotation. Samples were 
centrifuged at 25,830 g for 10 minutes, and pellets were discarded. Protein concentrations 
were measured with BCA protein assays. 
Protein reduction and alkylation was carried out with 5 mM DTT (30 minutes, 56 
°C) and 14 mM iodoacetamide (25 minutes, room temperature in the dark), respectively. 
Proteins were separated through methanol-chloroform precipitation. Briefly, methanol, 
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chloroform and water were added to one part sample at a 4:1:3 ratio, and centrifuged at 
4696 g for 10 minutes. The top layer was removed, the same volume of methanol was 
added again, and samples were centrifuged at 4696 g for 10 minutes. Supernatant was 
discarded and protein pellets were dried.  
Proteins were resuspended in buffer containing 50 mM HEPES (pH 7.9), 5% 
(vol/vol) acetonitrile, and 0.1 M urea, and digested with Lys-C (1:200 enzyme:protein 
ratio) at 31 °C. The next day, 13 µg trypsin was added and samples were incubated 4 
hours at 37 °C. Digestions were quenched with trifluoroacetic acid (TFA) until pH was 
below 2, and centrifuged to discard precipitate. Peptide samples were desalted on a tC18 
Sep-Pak cartridge and split for whole proteome (~30 µg) and surface N-glycoprotein 
analysis (~6 mg). 
3.2.3 Surface N-glycoprotein analysis 
Cell surface N-glycopeptides tagged with biotin were separated by NeutrAvidin 
agarose and desalted as described previously (Section 2.2.3). Each sample (0, 4 or 8 day 
treated) was split in two for duplicate quantitative analysis with TMTsixplex labeling. 
The 0 day treated samples were labeled with TMT6-126 and TMT6-127, 4 day treated 
samples with TMT6-128 and TMT6-129, and 8 day treated samples with TMT6-130 and 
TMT6-131.22 After quenching the TMT reaction with 5% hydroxylamine, all six channels 
were combined, dried, and desalted with a tC18 SepPak cartridge. Samples were dried 
overnight, dissolved in 50 mM NH4HCO3 in heavy-oxygen water, and then subjected to 
deglycosylation with PNGase F. During the three hour reaction, N-glycans were removed 
from asparagine residues and simultaneously deaminated to form aspartic acid; since this 
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reaction is carried out in heavy-oxygen water, 18O is incorporated and serves as a mass 
tag for glycosylation site identification. After 3 hours, the reaction was quenched with 
formic acid until pH was below 2. Samples were then purified with stage tips and dried 
for LC-MS/MS analysis. 
3.2.4 Whole proteome analysis 
Two samples at each time point (0, 4 or 8 day) were used for duplicate 
quantitative analysis. The same TMT reagents were used as described above (0 day: 
TMT6-126 and TMT6-127, 4 day: TMT6-128 and TMT6-129, 8 day: TMT6-130 and 
TMT6-131). Labeling reactions were quenched with 5% hydroxylamine and 1% of each 
channel was combined and analyzed with LC-MS/MS to determine the correct volumes 
of each to mix in order to have a 1:1:1:1:1:1 ratio. Corresponding volumes of each 
channel were mixed, and the combined sample was dried before desalting with a tC18 
Sep-Pak cartridge. 
Peptides from the proteome sample were fractionated by high pH reversed-phase 
HPLC, using a 40 minute gradient of 5-55% 10 mM ammonium formate in 90% ACN, 
pH 10. Twenty fractions were collected, dried, and purified with stage tips before 
analysis with LC-MS/MS. 
3.2.5 LC-MS/MS analysis 
Purified glycopeptide samples were resuspended in 5% ACN and 4% TFA, and 
analyzed on the same microcapillary HPLC and LTQ Orbitrap Elite as described in 
Section 2.2.4. Here, a 90 minute gradient of 4-17% ACN (containing 0.125% FA) was 
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used to separate each glycopeptide sample before detection in the LTQ Orbitrap Elite. 
Each detection cycle included one full MS scan (resolution: 60,000) in the Orbitrap at the 
Automatic Gain Control (AGC) target of 1 million, followed by up to 15 MS/MS of the 
most intense ions in the Orbitrap.  
Whole proteome samples were analyzed on the same instrument, with varying 90 
minute gradients for the 20 fractions. The gradient for the first five fractions was 2-15% 
ACN (containing 0.125% FA), the second five was 3-17% ACN (containing 0.125% FA), 
the third five was 4-20% ACN (containing 0.125% FA), and the final 5 was 8-27% ACN 
(containing 0.125% FA). The same detection cycles as above were used for data-
dependent acquisition in the Orbitrap. 
3.2.6 Data analysis 
Database searching and filtering for glycopeptides was the same as described in 
Section 2.2.5, with the addition of the fixed modification on lysine and the N-terminus 
for TMT labeling (+229.162932). Peptides from whole proteome experiments were 
searched using the same database, with only the modifications oxidation of methionine 
(+15.9949) and carbamidomethylation of cysteine (+57.0214). For protein analysis, 
peptides were filtered to a less than 1% FDR, followed by further filtering to achieve less 
than 1% FDR at the protein level. 
3.2.7 Glycosylation site localization 




3.2.8 Quantification analysis 
Glycopeptides and peptides were quantified using the TMT reporter ion intensities 
in the tandem mass spectra. Isotopic information provided by Thermo was used to 
calibrate the measured intensities. TMT intensities were averaged for each channel, and 
then normalized accordingly before subsequent analysis. Median peptide ratios for each 
unique peptide were calculated for each TMT channel, and median protein ratios were 
calculated from all unique peptides identified within a protein for each TMT channel. 
Duplicate channels for each sample (126 and 127, 128 and 129, and 130 and 131) were 
averaged to obtain abundance ratios at each stage of treatment (0, 4 or 8 days, 
respectively). 
3.3 Results and Discussion 
3.3.1 Experimental procedure 
TGF-β has been shown to induce EMT in MCF 10A cells, which are non-
tumorigenic epithelial mammary cells.23 Different time points throughout EMT were 
chosen, i.e. cells were harvested after TGF-β treatment for 0, 4 and 8 days. Untreated 
MCF 10A cells are rounded, but after treatment with TGF-β, cells lose cell adhesion 
properties and become more elongated in shape.5 After treatment for 0, 4 or 8 days, cells 
were labeled with GalNAz for 48 hours, and subjected to a copper-free click reaction 
under physiological conditions before harvest. After digestion, peptides were split in two 
for whole proteome and surface glycopeptide analysis. Peptides from whole proteome 
samples were fractionated by high pH reversed-phase HPLC, and protein abundances 
throughout the transition were quantified by TMT labeling and LC-MS/MS. 
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Glycopeptides were enriched with NuetrAvidin agarose and treated with PNGase F in 
heavy-oxygen water to generate a common tag for glycopeptide and glycosylation site 
identification. Prior to TMT labeling, each sample was split in two for duplicate 




Figure 3.1. Experimental procedure to quantify surface glycoproteins changing 
throughout EMT. 
 








Cu-free click reaction with DBCO-sulfo-biotin
Harvest, lysis, digestion
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An example tandem mass spectrum corresponding to the glycopeptide 
ENQN#HSYSLK (# denotes glycosylation site) is shown in Figure 3.2A. This peptide is 
from integrin alpha-V (ITGAV), which is a receptor for a variety of proteins, including 
fibrinogen, laminin and vitronectin. ITGAV is also a subunit of αvβ3 integrin and αvβ6 
integrin, which are both up-regulated during EMT and contribute to invasive 
properties.24-26 The red box in Figure 3.2A indicates the m/z range where TMT reporter 
ions are located, which is enlarged in Figure 3.2B. The abundance of this peptide 
increases after 4 days of treatment, which is consistent with the high expression of 
ITGAV during EMT, and then decreases slightly at 8 days. It is possible that by day 8, 
cells have transitioned completely to mesenchymal and therefore the expression of 
ITGAV is not as high as compared to day 4 during the transition.  
3.3.2 Glycopeptide quantification 
A total of 438 unique N-glycopeptides corresponding to 235 glycoproteins were 
quantified here. Duplicate abundances were measured for 0, 4 and 8 day samples, which 
allowed us to evaluate measurement reproducibility. Figure 3.3 shows the reproducibility 
between duplicate ratios for glycopeptides quantified after 4 day (Figure 3.3A) and 8 day 
(Figure 3.3B) treatment. Duplicate intensities from untreated cells were averaged, and 
intensities from 4 and 8 day cells were each divided by the untreated average to generate 
the plot. Glycopeptide ratios were very reproducible between duplicates, as shown by the 





Figure 3.2. Example tandem spectrum for the peptide ENQN#HSYSLK (# denotes 
glycosylation site) which is from integrin alpha-V, showing (A) peptide fragments 
and (B) TMT ratios used for quantification. The abundance of this peptide 
increased after TGF-β treatment for 4 days, and decreased slightly by 8 days of 
treatment. 
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Figure 3.3. Reproducibility of glycopeptide quantification in TMT duplicates for (A) 
4 day and (B) 8 day treated versus untreated cells. 
 
The majority of surface N-glycopeptides were neither up- nor down-regulated 
after 4 or 8 days of treatment with TGF-β, i.e. 351 and 329, respectively, but there were a 
group of glycopeptides that were up- or down-regulated at each time point. Overall, 39 
glycoproteins were down-regulated over the 8 day treatment, and 37 were up-regulated 









































throughout that time. However, the abundances of 103 glycoproteins increased after 4 
days of treatment, which may imply that many glycoproteins are intermediates 
throughout EMT, and are over-expressed during the transition, and then decrease after the 
transition is complete. Another potential explanation for the majority of glycoproteins 
being non-regulated throughout the 8 day treatment is that perhaps the glycans are 
playing a more dynamic role in the surface properties throughout EMT. Glycopeptides 
containing only one glycosylation site and a ModScore greater than 13 were normalized 
to their corresponding protein ratios quantified in the whole proteome experiment, and 
their adjusted values are shown in Figure 3.4A and 3.4B. After protein normalization, 
glycopeptide abundance ratios shift towards down-regulation. This shift indicates that 
glycosylation is regulated as a result of TGF-β treatment, in addition to general protein 
expression. 
Integrins are a group of transmembrane receptor proteins that play critical roles in 
cell adhesion and extracellular matrix interactions. Four integrins quantified here 
correlate very well to expression changes that have been previously reported during 
EMT: ITGA6 was down-regulated, and ITGA5, ITGB1 and ITGB6 were up-regulated 
(Figure 3.5A, Table 3.1). As mentioned above, αvβ6 integrin has increased expression 
during EMT, as well as α5β1 integrin, which binds fibronectin, stimulates cell migration 
and is also up-regulated during EMT.27-28 ITGA6 was quantified as down-regulated here, 
and α6β4 integrin has been reported to be down-regulated during EMT.29 Three integrins 
quantified here, ITGA10, ITGB5 and ITGB8, have not been reported to be correlated 







Figure 3.4. Distribution of glycopeptide abundance ratios before and after 
normalization with protein ratios at (A) 4 and (B) 8 days of TGF-β treatment (bin 































































Figure 3.5. Integrins quantified in this work, including those (A) consistent with 

















































Table 3.1. Selected integrins and their corresponding glycosylation site and protein ratios after 4 and 8 days of TGF-β 
treatment (# denotes glycosylation site). 
Gene 

























IYLRN#ESEFR 593 1000 0.85 0.69 2.25 1.31 
NLN#NSQSDVVSF
R 773 24.4 1.06 0.86 1.74 1.01 
VTGLN#CTTNHPI
NPK 868 31.3 1.49 1.21 2.02 1.18 
ITGA6 
 








R 930 73.3 1.19 0.73 0.88 0.91 
YQTLN#CSVNVN










NGVN#GTGENGR 406 73.3 0.55 0.37 0.71 0.50 
DTCTQECSYFN#I
TK 669 1000 4.20 2.86 2.80 1.98 
ITGB6 EVEVN#SSK 463 1000 1.94 3.95 0.49 2.34 4.10 0.57 Integrin beta-6 
 
 
3.3.3 Whole proteome analysis 
Peptides from the whole proteome sample was fractionated into 20 samples with 
high pH reversed-phase HPLC after digestion, and subsequently analyzed with LC-
MS/MS. A total of 4656 proteins were quantified throughout EMT (0, 4 and 8 day treated 
cells); the distribution of protein abundance ratios after 4 and 8 days of TGF-β treatment 
are shown in Figure 3.6A. The majority of proteins were not consistently up- or down-
regulated over the 8 day treatment; 534 proteins were down-regulated and 699 proteins 
were up-regulated. 
Selected proteins with the largest increase in abundance over 8 days of TGF-β 
treatment are shown in Figure 3.6B, and those with the largest decrease in abundance 
over treatment time are in Figure 3.6C. The five most highly up-regulated proteins are 
implicated in a variety of cellular processes: FTH1, ferritin heavy chain, is important for 
iron homeostasis, and is also involved in cell proliferation. FTH1 has been shown to be 
induced during cellular transformation and enhanced by oncogenic signaling.30 RIN2, 
Ras and Rab interactor 2, is involved in GTPase activation, and has been previously 
reported to be a target of the Ras/ERK1/2 pathways which are involved in mesenchymal 
transformation in pancreatic cancer cells.31 
The five proteins with the largest decrease in abundance are involved in DNA 
replication and repair, RNA binding, and translation. HMGN3, high mobility group 
nucleosome-binding domain-containing protein 3, regulates chromatin structure and 
related processes such as transcription and DNA repair, and PDS5B, sister chromatid 
cohesion protein PDS5 homolog B, is involved in DNA replication and repair. RNA-
 64 
 
binding proteins include BRIX1, ribosome biogenesis protein BRX1 homolog, and 
HNRNPC, heterogeneous nuclear ribonucleoproteins C1/C2. RPL36AL, 60S ribosomal 
protein L36a-like, is a structural constituent of the ribosome.32 
3.3.4 Clustering of up- and down-regulated proteins 
Up- and down-regulated proteins were each clustered with the Database for 
Annotation, Visualization and Integrated Discovery (DAVID, version 6.8)33-34 based on 
biological process, and the highest enriched processes are shown in Figure 3.7. Processes 
that were highly enriched among up-regulated proteins include transport and oxidation-
reduction process. Interestingly, processes highly enriched among down-regulated 
proteins include translation initiation and ribonucleoprotein complex biogenesis. 
Molecular function clustering revealed that down-regulated proteins corresponding to 
RNA binding are the most highly enriched (P = 7.69E-87), which together implies that 
translation may be modulated during EMT. There were 215 proteins correlated to RNA 
binding, a selection of which are shown in Table 3.2.  These clustering results are 
consistent with the functions of the five proteins with the largest decrease in abundance 





Figure 3.6. Proteome quantification results: (A) protein ratio distribution after 4 
and 8 days of TGF-β treatment (bin size is 0.5), (B) examples of proteins with the 
greatest increase in abundance after 8 days of treatment, and (C) examples of 










































































Interestingly, several molecular functions were highly enriched in both up- and 
down-regulated proteins, including cadherin binding and protein binding involved in cell-
cell adhesion. The molecular functions listed in DAVID are general and therefore 
cadherin binding could refer to E-cadherin in down-regulated proteins and N-cadherin in 
up-regulated proteins. Similarly, cell adhesion related proteins may be highly dynamic 
throughout EMT, because cells lose their association with epithelial cells and have an 
increased affinity for mesenchymal cells throughout EMT.35 Therefore, protein binding 
involved in cell-cell adhesion can be highly enriched in up- and down-regulated proteins. 
 
Figure 3.7. Clustering of (A) up- and (B) down- regulated proteins according to 
biological process. 





































Q99700 ATXN2 2 0.51 0.28 Ataxin-2 

















P63173 RPL38 6 0.58 0.35 60S ribosomal protein L38 




P62280 RPS11 13 0.62 0.28 40S ribosomal protein S11 
Q15024 EXOSC7 2 0.64 0.47 Exosome complex component RRP42 





Q9NPE3 NOP10 2 0.66 0.22 
H/ACA 
ribonucleoprotein 







EMT is an integral process in cells, contributing to development and healing, and 
can be adapted and exploited for migration and tumor metastasis. Cell surface 
glycoproteins play critical roles in cell-cell adhesion and extracellular interactions, and 
are implicated in EMT. Here we have quantitatively and site-specifically investigated 
surface N-glycoprotein changes throughout EMT by employing metabolic labeling, 
copper-free click chemistry, and multiplexed proteomics techniques. Overall, 39 
glycoproteins were down-regulated and 37 were up-regulated in MCF 10A cells after 8 
day treatment with TGF-β. Glycoprotein analysis before and after normalization with 
corresponding parent protein ratios indicate that glycosylation is indeed modulated 
throughout EMT, in addition to protein expression. Whole proteome analysis revealed 
down-regulated proteins to be highly enriched with RNA and translation processes, 
indicating that translation is modified during EMT. These results provide insight into 
site-specific surface glycoprotein changes and whole proteome expression modulation as 
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4.1 Introduction 
Protein secretion plays extremely important roles in nearly every extracellular 
activity, including cell-cell communication, cell-matrix interactions, and cellular immune 
response.1 Secreted proteins are often reflective of the developmental and disease status 
of the cell, including cell differentiation and cancer cell metastasis. Therefore, secreted 
proteins can provide valuable disease information, and secreted proteins in bodily fluids 
are highly promising, non-invasive biomarkers for disease detection and surveillance.2,3  
 There are two types of protein secretion pathways in cells: classical and non-
classical secretion. Non-classical secretion is very elusive, but several ways have been 
reported for the secretion of proteins lacking signal peptides.4-6 In classical secretion, 
proteins containing an N-terminal signal peptide are synthesized in the ribosome, and 
translocated to the endoplasmic reticulum (ER), where proteins are glycosylated and 
folded. They are subsequently transported to the Golgi for further modification, and 
eventually are sent to the extracellular space by secretory vesicles.7 Protein N-
glycosylation plays extraordinary roles in protein folding and trafficking, frequently 
determines protein stability, and regulates protein interactions with other proteins or 
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ligands.8-12 For instance, the secretion of a group of proteins may be regulated by their 
glycosylation while glycosylation on other proteins may play different roles, such as 
regulating their interactions with other molecules or protecting proteins from degradation. 
However, systematic and quantitative investigation of protein secretion and the 
correlation with glycosylation remains to be explored. In this work, yeast was used as a 
model eukaryotic system to systematically study protein secretion, and quantify secreted 
protein and glycoprotein abundance changes as a result of N-glycosylation inhibition via 
tunicamycin. 
Although computational approaches can provide some information regarding 
protein secretion, specifically by identifying signal peptides, there is still uncertainty 
regarding the sequences of signal peptides.13-14 In addition, computational methods have 
been developed based on experimental results, and often computational results need to be 
further verified through experimental procedures. Many non-classically secreted proteins 
are also more difficult to be predicted through computation. Therefore, there is an urgent 
need to study protein secretion experimentally. It is challenging to systematically 
investigate secreted proteins and glycoproteins in mammalian cell lines.15-16 First, it is 
difficult to distinguish secreted glycoproteins from those in the original culture medium 
containing fetal bovine serum (FBS). Because of protein conservation, many tryptic 
peptides from proteins secreted from mammalian cells and those in FBS share the same 
sequences. Second, highly abundant proteins from FBS (typically 10% in media) prevent 
the global identification of low-abundance secreted proteins and glycoproteins by current 
methods. Depleting the media of serum is commonly used to study secreted proteins in 
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mammalian cells,17-18 although this alteration may act as a stimulus during cell growth.19-
21 
Mass spectrometry (MS)-based proteomics has made great strides over the past 
decade, which provides the possibility to globally analyze proteins and their 
modifications.22-33 However, due to the complexity of biological samples and wide range 
of protein abundances, it is very challenging to reach proteins with low abundance.17, 34-35 
Many secreted proteins and glycoproteins fall into this category and their comprehensive 
identification requires several challenges to be overcome. For example, they are present 
at much lower abundances compared to the majority of intracellular proteins. 
Correspondingly, the death of any individual cells during cell growth or subsequent 
experimental steps results in the release of intracellular proteins into the media where 
secreted proteins are located. Due to the vast differences in abundances, these 
intracellular proteins will mask the identification of low-abundance secreted proteins 
during mass spectrometry analysis. For comprehensive analysis, secreted proteins ideally 
would be completely isolated from cells, therefore preventing intracellular protein 
contamination. However, highly effective separation of secreted proteins is not trivial 
when working with living cells. Centrifugation is the most widely used method for cell 
harvest, but even common centrifugation speeds may cause cells to break open, therefore 
releasing intracellular proteins into the media before separation.  
Additionally, comprehensive analysis of protein modifications is a daunting task 
due to their sub-stoichiometry, occurrence on low-abundance proteins and dynamic 
nature.36-42 Effective enrichment prior to MS analysis is typically required for complex 
biological samples, including whole cell lysates and serum samples.23, 43-47 It is even more 
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challenging to globally analyze protein glycosylation compared to other types of 
modifications because glycans are incredibly diverse.48-57 The high heterogeneity of 
glycans is incompatible with the typical large-scale identification of protein modifications 
by MS, which requires a common tag. Furthermore, the variety of glycans also makes the 
enrichment of glycopeptides much more difficult. Considering that many secreted 
proteins are glycoproteins that contain relevant disease information, there is a long-
standing interest to analyze glycoproteins in the secretome.16, 58-59 However, 
comprehensive analysis of protein N-glycosylation in the yeast secretome has yet to be 
reported. 
By combining stable isotope labeling of amino acids in cell culture (SILAC)60 
with MS-based proteomics, we systematically investigated secreted proteins and 
glycoproteins in yeast. After inhibiting protein N-glycosylation for several hours, we 
found many secreted proteins were down-regulated, while the abundances of some 
secreted proteins were relatively unaffected. We also comprehensively and site-
specifically studied glycoproteins in the secretome. For the first time, we systematically 
investigated secreted proteins and glycoproteins with and without the inhibition of 
protein N-glycosylation in Saccharomyces cerevisiae, which can provide a better 
understanding of protein secretion and glycosylation. 
4.2 Experimental Methods 
4.2.1 Yeast cell growth, collection of secreted proteins and mixing 
Biological triplicate experiments were performed, and for each triplicate, yeast 
was inoculated overnight in Lys-dropout media (2.0 g/L SCM-Lys, 6.7 g/L Yeast 
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Nitrogen Base without Amino Acids, 20 g/L dextrose) supplemented with Lys0. The 
following day, the overnight culture was diluted into two flasks with 200 mL of Lys-
dropout media and 76 mg/L Lys8 (Heavy) or Lys0 (Light) until the optical density (OD) 
at 600 nm was ~0.1. Cells were incubated at 30 °C with shaking at 250 rpm. When the 
OD was ~0.55, either 2 µg/mL tunicamycin or the same volume (40 µL) of dimethyl 
sulfoxide (DMSO) was added to heavy or light cells, respectively. After cells were 
incubated for half an hour, the media was changed by centrifuging cells at 1000 g for 5 
min, discarding supernatants and resuspending the cell pellets in new media (Lys-dropout 
media, plus Lys8 and tunicamycin, or Lys0 and DMSO). Cells were incubated for two 
hours and finally harvested by centrifugation as gently as possible to minimize extra 
pressure on the cells that would cause cell death and corresponding lysis; acceleration 
and deceleration rates were decreased to accommodate these concerns. First, cell 
suspensions were centrifuged at 500 g for 10 minutes. Supernatants were carefully 
transferred to new tubes and centrifuged again at 1000 g for 10 minutes. Then 
supernatants were transferred to new tubes and centrifuged again at 4696 g for 10 
minutes. Supernatants were transferred again into new tubes, and heavy and light media 
was mixed based on the OD at 600 nm at the time of tunicamycin or DMSO treatment. 
The OD is directly correlated to the number of cells per unit volume. The measured ODs 
were converted into the number of cells in corresponding volumes of cultured media, and 
then media were mixed based on the same number of cells from each sample. Mixed 
media was subsequently concentrated on 10 kDa filters until the volume was ~1.0 mL. 
4.2.2 Protein reduction, alkylation, precipitation and digestion 
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Disulfide bonds within proteins were reduced with 5 mM DTT for 25 minutes at 
56 °C, and subsequently alkylated with 14 mM iodoacetamide for 30 minutes at room 
temperature in the dark. Proteins were precipitated with the methanol chloroform 
precipitation method and the resulting protein pellet was dried in a speed-vacuum 
concentrator (Labconco).61 Proteins were resuspended in a buffer with 50 mM HEPES 
(pH=7.9), 0.1 M urea and 5% ACN, and digested with 70 µg Lys-C overnight at 31 °C 
with shaking. Digestions were quenched by acidification with trifluoroacetic acid until 
the pH was ~2. Digests were purified with a 50 mg SepPak tC18 cartridge and separated 
into two: 10% for protein analysis and 90% for glycoprotein analysis. 
4.2.3 Protein analysis 
Dried peptides were further purified with the stage-tip method and fractionated 
into three samples during elution with 20%, 50% or 80% ACN containing 0.1% FA, 
respectively. Samples were dried and analyzed with an on-line LC-MS/MS system, and 
different fractions were separated with different LC gradients prior to MS analysis 
(described below). 
4.2.4 Protein N-glycosylation analysis 
Dried peptides were enriched with boronic acid conjugated magnetic beads as 
reported previously.62 Reversible covalent interactions between glycans and boronic acid 
were formed under basic conditions. After removing non-glycosylated peptides, 
glycopeptides were eluted from the beads under acidic conditions. Enriched 
glycopeptides were dried, and then desalted with a SepPak tC18 cartridge. Purified 
glycopeptides were further dried overnight in the speed-vacuum concentrator. 
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Completely dried glycopeptides were incubated with PNGase F in heavy-oxygen water 
(H218O) for 3 hours at 37 °C, as described previously (Section 2.2.3). Similarly, samples 
were purified with the stage-tip method, and separated into three fractions with 20%, 
50% or 80% ACN containing 0.1% FA. Finally, samples were dried, and then dissolved 
in a solvent containing 5% ACN and 4% FA for LC-MS/MS analysis. 
4.2.5 LC-MS/MS analysis 
The same UltiMate HPLC system outlined in previous chapters was used here to 
fractionate peptides prior to MS analysis. For secreted protein samples, the first fraction 
was separated using a gradient of 4-13% ACN (with 0.125% FA), the second one using 
the gradient of 6-30% ACN (with 0.125% FA) and the third was 9-37% ACN (with 
0.125% FA). For glycosylation samples, the first fraction was separated using a gradient 
of 3-22% ACN, the second was 6-30% and the third was 12-45% ACN (with 0.125% 
FA). Samples were detected in a LTQ Orbitrap Elite, as described previously (Section 
2.2.4).  
4.2.6 Data analysis 
Raw files recorded by MS were converted into mzXML format, and searched 
using the SEQUEST algorithm (version 28)63 against a database encompassing sequences 
of all proteins (6607 protein entries) in the yeast ORFs database downloaded from SGD 
(http://www.yeastgenome.org/). FDRs of each peptide was estimated, as described 
previously. The following parameters were used for the database search: 20 ppm 
precursor mass tolerance; 1.0 Da product ion mass tolerance; Lys-C digestion; up to three 
missed cleavages; variable modifications: oxidation of methionine (+15.9949) and 18O 
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tag on Asn (+2.9883) for glycosylation samples; fixed modifications: 
carbamidomethylation of cysteine (+57.0214). LDA was used to distinguish correct and 
incorrect peptide identifications, as described previously. For protein glycosylation 
analysis, the data sets were restricted to only glycopeptides when determining FDRs, 
which can minimize the false positive identifications of glycopeptides. 
4.2.7 Glycosylation site localization 
ModScores were calculated to assign glycosylation site localizations and measure 
the assignment confidence, as described previously. We considered sites with a 
ModScore >19 (P < 0.01) to be confidently localized. 
4.2.8 Peptide quantification 
Proteins identified based on only one total peptide hit were removed from the 
datasets to increase the identification confidence. Quantified peptides were filtered based 
on S/N ratios for both heavy and light peptides. If a peptide (heavy or light) had an S/N 
ratio less than three, the corresponding peptide (light or heavy, respectively) was required 
to have an S/N ratio above five, otherwise the peptides were deleted. Peptides identified 
more than once were quantified by calculating the median value of all peptide area ratios 
to obtain a final peptide abundance change. Similarly, to quantify protein abundance 
changes, the median was calculated for all unique peptides for each protein to determine 
the final protein abundance change. 
For glycopeptide identification, after filtering, we manually checked some 
glycopeptides with relatively low XCorr values, especially for long peptides, and 
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removed them if their identifications were suspicious. Glycopeptides were quantified in 
the same way as described above. 
4.2.9 Bioinformatic analysis 
UniProt designations of extracellular, secreted, and membrane were used to 
determine which proteins in this dataset were located in these cellular components.64 
DAVID (Database for Database for Annotation, Visualization and Integrated Discovery) 
was also employed to confirm subcellular locations and to cluster proteins and 
glycoproteins.65 SignalP 4.1 was used to calculate which proteins contained a signal 
peptide sequence.13 
4.3 Results and Discussion 
4.3.1 Experimental procedure 
In this work, biological triplicate experiments were performed, which allows the 
assessment of reproducibility and increases the confidence of the identification and 
quantification of secreted proteins. In order to systematically investigate protein 
secretion, tunicamycin was chosen to treat cells because it has been widely used as a 
potent protein N-glycosylation inhibitor. In this SILAC experiment, heavy cells were 
treated with tunicamycin and mixed with light cells (treated with DMSO) at a 1:1 ratio. 
Secretomes were isolated and proteins were reduced, alkylated and precipitated before 
digestion with Lys-C overnight. Digested peptides were split into two for protein (10%) 
and glycosylation (90%) analysis, respectively. Glycosylation analysis included 
enrichment with boronic acid-conjugated magnetic beads, deglycosylation with PNGase 
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F in heavy-oxygen water, and purification with the stage-tip method before analysis with 
LC-MS/MS. The experimental procedure for each triplicate is shown in Figure 4.1.  
 
 
Figure 4.1. Experimental setup for each triplicate to study secreted proteins and 
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4.3.2 Example of secreted protein identification and quantification 
An example of peptide identification and quantification are shown in Figure 4.2, 
including a full mass spectrum, tandem mass spectrum and extracted elution profiles for 
the heavy and light versions of the peptide YGSDGLSMTLAK* (* denotes heavy 
lysine). The light version of the peptide was identified from untreated cells and the heavy 
peptide was from treated cells; the full MS is displayed in Figure 4.2A. As shown in 
Figure 4.2B, the heavy peptide was very confidently identified with an XCorr of 3.65, 
and mass accuracy of 0.88 ppm. This peptide is from the protein YGR189C, probable 
glycosidase CRH1, which plays a role in cell wall architecture. Based on the elution 
profiles from light and heavy versions of the peptide, we were able to quantify the 
abundance change of this peptide with a ratio of 0.37 (Figure 4.2C). Because each of the 
elution profiles contains many scans, the ratio was highly accurate. This protein was 
quantified based on 43, 40 and 35 total peptides in each experiment, respectively, and the 
ratios are very consistent, i.e. 0.37, 0.39 and 0.37. All proteins identified and quantified in 






Figure 4.2. Example spectra for peptide identification and quantification. (A) Full 
mass spectrum showing heavy and light peptides, (B) tandem mass spectrum for 
peptide identification and (C) elution profiles of heavy and light versions of the 
peptide for quantification. 
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4.3.3 Secreted protein identification and quantification in biological triplicate 
experiments 
Overall the number of proteins identified in each of the three triplicate 
experiments was very consistent: 198, 185 and 186 proteins, respectively. Figure 4.3A 
shows the overlap between proteins identified in each triplicate; 144 proteins were 
identified in all three experiments, and 180 were identified in at least two experiments. A 
total of 245 secreted proteins were identified. 
Gene ontology analysis with DAVID was performed to determine which cellular 
components, molecular functions and biological processes corresponded to the 180 
proteins identified in at least two triplicates and the results confirmed the presence of 
mainly secreted proteins (Figure 4.3). First, cellular component clustering revealed that 
the extracellular region was highly enriched with an extremely low P value of 5.90E-33, 
in addition to fungal-type cell wall (9.83E-36), external encapsulating structure (1.73E-
35) and plasma membrane (1.38E-15). Interestingly, ribosomal proteins were also 
enriched. Previous reports indicate that some ribosomal proteins can be located on the 
cell surface or in the extracellular space, which is a possibility here.66 Although they also 
could be due to cell death, the presence of many ribosomal proteins and their enrichment 
in the dataset compared to other intracellular proteins suggests that these proteins could 
be intentionally secreted. Molecular function and biological process analysis showed 
further cell wall and extracellular functions highly enriched in the dataset, including 
hydrolase activity, cell wall organization and glucanosyltransferase activity (Figure 4.3). 
Proteins with hydrolase activity (acting on glycosyl bonds) identified in at least two 





Figure 4.3. Proteins identified in each triplicate. (A) Overlap of proteins identified 





































0 5 10 15 20 25
structural constituent of ribosome
hydrolase activity, acting on
glycosyl bonds

















SGA1 YIL099W 2 8 0.02 Intracellular sporulation-specific glucoamylase involved in glycogen degradation 
CRH1 YGR189C 9 118 0.37 Chitin transglycosylase that functions in the transfer of chitin to beta(1-6) and beta(1-3) glucans in the cell wall 
SUN4 YNL066W 3 27 0.39 Cell wall protein related to glucanases, possibly involved in cell wall septation 
SUC2 YIL162W 10 23 0.08 Invertase, sucrose hydrolyzing enzyme 
ATH1 YPR026W 14 35 0.06 Acid trehalase required for utilization of extracellular trehalose 
PGU1 YJR153W 4 12 1.45 Endo-polygalacturonase, pectolytic enzyme that hydrolyzes the alpha-1,4-glycosidic bonds in the rhamnogalacturonan chains in pectins 
BGL2 YGR282C 8 60 0.64 Endo-beta-1,3-glucanase, major protein of the cell wall, involved in cell wall maintenance 
EGT2 YNL327W 8 106 0.03 GPI-anchored cell wall endoglucanase required for proper cell separation after cytokinesis 
SCW4 YGR279C 13 175 0.15 Cell wall protein with similarity to glucanases 
EXG2 YDR261C 7 21 0.23 Exo-1,3-beta-glucanase, involved in cell wall beta-glucan assembly 
EXG1 YLR300W 8 142 0.19 Major exo-1,3-beta-glucanase of the cell wall, involved in cell wall beta-glucan assembly 
CTS1 YLR286C 3 30 0.34 Endochitinase, required for cell separation after mitosis 
DSE4 YNR067C 13 60 0.46 Daughter cell-specific secreted protein with similarity to glucanases 
SCW10 YMR305C 10 80 0.89 Cell wall protein with similarity to glucanases 
UTR2 YEL040W 3 37 0.31 Chitin transglycosylase that functions in the transfer of chitin to beta(1-6) and beta(1-3) glucans in the cell wall 
SCW11 YGL028C 5 192 0.25 Cell wall protein with similarity to glucanases 
DSE2 YHR143W 1 7 0.48 Daughter cell-specific secreted protein with similarity to glucanases 
 
 
 A total of 192, 179 and 179 proteins were quantified in each of the three triplicate 
experiments, respectively. Most of them were down-regulated, i.e. 151, 145 and 134 
proteins, in tunicamycin-treated cells labeled with heavy lysine. Protein ratios quantified 
in the three experiments are highly reproducible, as demonstrated in Figure 4.4A through 
comparison between the first and second experiments (R=0.92) and the first and third 
experiments (R=0.93). Deviations could be due to variations in protein abundances 
among cells in biological triplicate experiments. In addition, sample preparation and MS 
measurements could also result in experimental errors. 
A total of 239 proteins were quantified in the triplicate experiments. 174 proteins 
were quantified in at least two experiments, among which 135 were down-regulated and 
21 were up-regulated; the protein median ratio distributions are shown in Figure 4.4B. 
For down-regulated proteins, their secretion is very likely regulated by glycosylation. 
After protein glycosylation is inhibited by tunicamycin, proteins will not be folded 
properly and as a result will be trapped inside cells. For proteins with increased 
abundances after the treatment, it is clear that their secretion is not dependent on protein 
glycosylation. Their expression was up-regulated due to cellular responses to the 
tunicamycin treatment. For example, HSP12 was up-regulated by 3.4 fold in the 
secretome. This is a plasma membrane localized protein that protects membranes from 
desiccation; and its expression is induced by external stimulus including heat shock, 
oxidative stress and osmostress. In our previous research, this protein was up-regulated 
by 3.1 fold in cells treated by tunicamycin for the whole cell lysate analysis.47 This is 
further supported by gene ontology clustering according to biological process. As shown 
in Figure 4.5, among 21 up-regulated proteins, eight proteins were related to response to 
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oxidative stress, which is the most highly enriched group with a P value of 8.0E-9. 
Biological processes corresponding to cell redox homeostasis, response to temperature 
stimulus and homeostatic process, were also highly enriched in up-regulated proteins. 
 
Figure 4.4. Secreted proteins quantified in all three triplicates. (A) Comparison of 
quantified secreted proteins between the first and second experiments (top) and the 
first and third experiments (bottom), and (B) the median ratio distribution of 




























































Figure 4.5. Clustering of 21 up-regulated proteins quantified in at least two 
triplicates according to biological process. 
 
This study provides the first systematic identification of secreted proteins in 
Saccharomyces cerevisiae. A total of 245 secreted proteins were identified; 144 proteins 
were found in all three experiments and 180 proteins were identified in at least two 
experiments. After cells were treated with tunicamycin for two hours, secreted protein 
quantification results demonstrated that many proteins were down-regulated. The down-
regulation of these proteins strongly suggests they are secreted through the classical 
pathway and their secretion is very likely regulated by protein N-glycosylation. 
4.3.4 Site specific analysis of protein glycosylation in the secretome 
The enrichment of glycopeptides is essential for their MS-based identification and 
quantification, and the common tag generated through treatment with PNGase F in 
heavy-oxygen water enabled us to confidently identify glycopeptides and localize the 
glycosylation sites. An example of glycopeptide identification 
(YSRCDTLVGN#LTIGGGLK, # represents glycosylation site) is shown in Figure 4.6. 
0 2 4 6 8 10
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This glycopeptide was confidently identified with an XCorr value of 5.58 and mass 
accuracy of 0.98 ppm. Based on the fragments, the glycosylation site was well localized 
at N57 with the well-known motif of NXS/T (X is any amino acid residue except 
proline). This glycopeptide is from the cell wall mannoprotein PST1 (YDR055W), which 
is a glycosylphosphatidylinositol (GPI)-anchored plasma membrane protein. Based on the 
information on UniProt, this protein is highly N-glycosylated and the site S419 is 
covalently attached to GPI. This glycopeptide was also quantified and down-regulated in 
all three glycosylation triplicates (0.13, 0.14 and 0.14, respectively). All glycosylation 
sites and glycopeptides quantified in triplicate experiments are listed in the Supporting 
Information online at doi.org/10.1021/acs.jproteome.6b00953. 
 
 
Figure 4.6. Tandem mass spectrum for the identification of the glycopeptide 
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A total of 110 unique glycosylation sites were identified in three glycosylation 
triplicate experiments, with 92, 78 and 83 sites in each, respectively, and their overlap is 
shown in Figure 4.7A. There were 60 glycosylation sites identified in all three triplicates, 
and 20 sites were localized to several domains, including thioredoxin, PLA2c, and 
peptidase a1 domains. Overall, the majority of glycosylation sites identified were not 
located within any domain (82%), as shown in Figure 4.7B (protein domain information 
is from UniProt). 
 
 
Figure 4.7. (A) Comparison of glycosylation site identification in triplicate 
experiments, and (B) the numbers of glycosylation sites (in at least two experiments) 
located within a domain or outside of any domain. 
 
Similarly, the numbers of glycopeptides and glycoproteins quantified were 
consistent in the glycosylation triplicate experiments: 89, 85, and 84 unique 
glycopeptides and 38, 36 and 38 glycoproteins, respectively. The overlap between 
glycopeptides quantified in each triplicate is shown in Figure 4.8. A total of 119 unique 









































distributions are shown in Figure 4.9A. Overall 47 glycoproteins were identified and 
quantified in the three triplicate experiments, 36 were quantified in at least two, and their 
protein ratio distribution is shown in Figure 4.9B. A total of 29 common glycoproteins 
were identified in all triplicate glycosylation experiments, with the majority of protein 
ratios down-regulated by more than two fold (27 down-regulated). The abundances of the 
other two proteins also decreased with ratios of 0.51 and 0.71; likely the secretion of 
these two proteins was also regulated by their glycosylation, but they may be relatively 
stable during treatment.  
Theoretically all glycopeptides and glycoproteins should be down-regulated after 
protein N-glycosylation inhibition by tunicamycin. However, several were not down-
regulated. The possible reasons include: the inhibition of protein N-glycosylation may not 
be complete; the parent protein abundance may be increased; some glycoproteins could 
be very stable, and their protein synthesis and degradation may not be rapid enough in 
terms of the time scale of the treatment. 
 
 


































Figure 4.9. Ratio distribution of (A) glycopeptides and (B) glycoproteins quantified 
in at least two triplicates. 
 
4.3.5 Clustering of glycoproteins 
The gene ontology clustering of the 36 overlapped proteins (using glycoproteins 






















































components were all related to cell membrane or extracellular categories, and vacuolar 
components (Figure 4.10), which also are involved in secretion. Protein clustering based 
on molecular function and biological process had similar results, including cell wall 
organization, carbohydrate metabolic processes and hydrolase activities, which are all 
expected to be involved in protein secretion or extracellular activities. 
4.3.6 GPI-anchored proteins and glycoproteins in the secretome 
GPI-modified proteins are typically anchored into the cell plasma membrane 
through the lipid component of the modified GPI. This group of proteins is normally 
located on the outside of the cell surface, and if the modified group gets cleaved or 
hydrolyzed, the protein will be released into the secretome. In this work, we identified a 
total of 14 GPI modified glycoproteins and 63 unique glycopeptides from these GPI-
anchored proteins. Several glycopeptides from GPI-anchored proteins are listed in Table 
4.2, along with their corresponding protein ratios. For example, GAS1, 1,3-beta-
glucanosyltransferase, is involved in cell wall biosynthesis and morphogenesis. The site 
N528 has been reported to be modified with GPI.67 In our experiments, we identified 6 
unique glycopeptides from this protein, and the glycopeptide with the site N95 is listed in 
Table 4.2. This glycopeptide was down-regulated with a median ratio of 0.22. The 
protein was also down-regulated in the secretome of the treated cells. All glycopeptides 






Figure 4.10. Clustering of glycoproteins in at least two triplicates according to (A) 






























Table 4.2. Several examples of glycopeptides quantified in at least two glycosylation triplicates from GPI-anchored proteins (P 
= 7.81E-17) (# denotes glycosylation site, and * denotes heavy lysine). 
Gene 




deviation Protein ratio Annotation 
ECM33 
VQTVGGAIEVTGN#F
STLDLSSLK 304 1000 0.13 0.005 0.14 Cell wall protein ECM33 SVRGGANFDSSSSN#
FSCNALK 328 47.1 0.33 0.043 
PST1 
YSRCDTLVGN#LTIG
GGLK 57 1000 0.14 0.008 
0.14 Cell wall mannoprotein PST1 IGGLDN#LTTIGGTLE
VVGN#FTSLNLDSLK 
292 120.5 0.14 0.012 
305 34.1 
CRH1 FHN#YTLDWAMDK 177 1000 0.13 0.007 0.13 Probable glycosidase CRH1 
YPS3 RN#ITLTTTK 275 1000 0.04 0.001 0.03 Aspartic proteinase yapsin-3 SLN#ASYSK 309 1000 0.03 0.005 






GK 313 8.0 0.07 0.008 0.07 Lysophospho-lipase 3 NYCWN#GTLDTTPLP
DVEK 588 42.1 0.03 0.103 
 
 
Another example is PLB3, phospholipase B (lysophospholipase), which is 
involved in phospholipid metabolism, hydrolyzes phosphatidylinositol and 
phosphatidylserine, and displays transacylase activity in vitro. We identified 5 unique 
glycopeptides, and two glycopeptides identified in all three triplicates are listed in Table 
2. Their ratios are 0.07 and 0.03, respectively, which further demonstrates the site 
specificity of this research. The majority of these glycopeptides were highly down-
regulated (all except one), and similarly the protein was also down-regulated in the 
secretome by 14.9 fold. In our previous experiment, this protein was up-regulated by 8.0 
fold inside of tunicamycin-treated cells.47 This is extremely consistent with the 
experimental design because the inhibition of N-glycosylation prevents the protein from 
being secreted, and therefore it accumulates inside cells. Examples such as this provide 
solid evidence that this protein’s secretion is regulated by its N-glycosylation. 
4.3.7 Comparison of secreted proteins and glycoproteins 
The glycoproteins quantified in at least two glycosylation triplicates were 
compared to the proteins quantified in at least two protein triplicates, and 27 proteins 
were overlapped (Figure 4.11A). The nine glycoproteins not identified in the triplicate 
protein experiments could be due to their low abundance and resultant lack of 
identification without any enrichment. Further investigation of these 27 proteins revealed 
that 25 were previously reported to be secreted (located in the extracellular matrix, 
plasma membrane, or containing a signal peptide), and the other two proteins were 
localized to the vacuole, indicating that they may also be secreted. All proteins except 
one were consistently down-regulated. The protein PRY3, whose function is unknown, 
was up-regulated at protein level with a ratio of 2.76, but the glycopeptide 
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YN#YSNPGFSESTGHFTQVVWK from this protein was down-regulated with a ratio of 
0.31. After protein glycosylation was inhibited, the glycopeptide was expected to be 
down-regulated. However, the increased abundance in the secretome means that this 
protein’s secretion is independent from its glycosylation. Clustering of 27 proteins 
present in all protein and glycosylation triplicates based on cellular component showed 
the extracellular region and cell wall to be highly enriched (P values of 2.79E-21 and 
9.51E-23, respectively).  
The majority of quantified proteins in at least two experiments, 135 of 174 total 
(77.6%), were down-regulated in the secretome of cells treated with tunicamycin. Most 
likely the secretion of these proteins was regulated by their glycosylation, since without 
N-glycosylation, they may not be properly folded and secreted. Among all down-
regulated proteins, 27 were also identified as glycosylated in the secretome, and nearly all 
of them (26 proteins) were down-regulated. This is another piece of solid evidence that 
the secretion of these 26 proteins were dependent on their N-glycosylation. 
4.3.8 Abundance distribution of identified secreted proteins 
Abundances of the 180 proteins identified in at least two protein triplicates were 
investigated to determine the depth of proteins quantified in this experiment. Figure 
4.11B shows the distribution of these proteins, and their abundances are from the 
literature.68 Although some proteins identified here are high abundance proteins (greater 
than 10,000 copies per cell), we also identified many low-abundance proteins. For 
example, 40 out of 180 proteins (22%) were not visualized and 8 proteins (4%) were not 
quantified in the previous report. From the distribution, the abundances of proteins 
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identified span a wide range. Due to the low abundance of many secreted proteins, if 
more starting materials are used, more proteins with low abundance should be identified. 
 
 
Figure 4.11. (A) Overlap between secreted proteins and glycoproteins quantified in 
at least two experiments. (B) Abundance distribution of 180 proteins identified in at 
least two protein triplicates according to protein abundance in the literature.68 
 
4.4 Conclusions 
Protein secretion is essential for cells to interact with the surrounding environment 
and other cells, and secreted proteins are a promising and non-invasive source of 




























profound implications in biological and biomedical research. By incorporating SILAC 
labeling, tunicamycin treatment and MS-based proteomics, secreted proteins in yeast 
have been comprehensively identified and quantified, and their glycosylation has been 
investigated for the first time. A total of 245 proteins were identified in triplicate 
experiments, with 144 common proteins identified in each of the three experiments. 
Protein clustering results indicated that proteins in the extracellular space were highly 
enriched. After cells were treated with a potent protein N-glycosylation inhibitor, 
tunicamycin, the majority of quantified secreted proteins were down-regulated, which 
strongly suggests that the secretion of these proteins was regulated by their N-
glycosylation, while the secretion of some proteins with minimal abundance changes was 
not related to glycosylation. In addition, we also systematically identified and quantified 
protein N-glycosylation in the secretome. Totally 110 glycosylation sites were located on 
47 secreted proteins. Nearly all quantified glycoproteins were down-regulated, which is 
consistent with the inhibition of protein N-glycosylation. By using yeast as a model 
eukaryotic system, we performed the first systematic study of protein secretion and its 
regulation by N-glycosylation. These experimental results provide valuable information 
about protein secretion and advance our understanding of protein secretion and the 
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CHAPTER 5. ENHANCING THE MASS SPECTROMETRIC 
IDENTIFICATION OF MEMBRANE PROTEINS 
Adapted with permission from the Royal Society of Chemistry 
Smeekens, J.M., Chen, W., Wu, R. Enhancing the mass spectrometric identification of 
membrane proteins by combining chemical and enzymatic digestion methods. Analytical 
Methods. 2015, 7 (17), 7220-7227. Copyright 2015 Royal Society of Chemistry. 
 
5.1 Introduction 
Membrane proteins play extremely important roles in biological systems and are 
crucial for a variety of cellular events including cell signaling, extracellular interactions 
and molecular transport.1-3 They also participate in various cellular functions, including 
adhesion, growth and metastasis, which contribute to disease progression.4-5 Additionally, 
because of their location on the cell surface, and resulting accessibility by 
macromolecules, membrane proteins are admirable for their potential as therapeutic and 
diagnostic targets.6-7 It has been estimated that about one third of the genome encodes 
membrane proteins,8 yet they represent 60-70% of FDA approved drug targets.9-10 The 
comprehensive analysis of membrane proteins will facilitate a better understanding of 
membrane protein function and lead to the identification of membrane proteins as 
effective biomarkers and drug targets.11 However, the hydrophobic nature and low 
abundance of membrane proteins hinders their global analysis.12-14 Modern mass 
spectrometry (MS)-based proteomics techniques have proven to be very powerful for 
global protein analysis.15-20 Common bottom-up proteomics techniques, where proteins 
are digested into peptides and subsequently analyzed with mass spectrometry,21-23 require 
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effective digestion wherein proteins remain solubilized so that proteases or small 
molecules can access cleavage sites.24 However, the accessibility of hydrophobic 
membrane proteins has been an existing problem because they tend to aggregate, 
precipitate and remain tightly folded in aqueous environments.13 
Enzymatic methods are most commonly used for protein digestion prior to MS-
based proteomics analysis. Several enzymes are frequently used, the most common being 
trypsin, which cleaves the peptide bond at the C-terminus of lysine and arginine residues 
(unless followed by a proline).25 Trypsin is preferred due to the relatively high 
abundances of lysine and arginine, and their distribution throughout proteins,26 which 
results in many peptides ideal for MS analysis. Other enzymes investigated here and 
frequently used for protein digestion include Lys-C and Glu-C. Lys-C cleaves at the C-
terminus of lysine residues,27 and Glu-C cleaves at the C-terminus of glutamic and 
aspartic acid residues.28 Membrane protein digestion with only enzymatic methods is 
challenging since bulky enzymes cannot access all cleavage sites within tightly folded 
hydrophobic proteins. As a result, digestion exclusively with enzymes is often not 
sufficient to achieve comprehensive analysis of membrane proteins. 
The inaccessibility of membrane proteins by proteases may be at least partially 
improved with chemical digestion methods, where small molecules can more easily 
access cleavage sites. However, chemical cleavage generally targets amino acids that are 
less abundant within proteins, which results in larger peptide fragments.29 For example, 
cyanogen bromide (CNBr) targets methionine residues and 2-nitro-5-thiocyanobenzoic 
acid (NTCB) targets cysteine residues.30 NTCB only cleaves reduced cysteine residues, 
so protein reduction is required before digestion can be performed. Digestion with NTCB 
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leads to two types of products, one is a N-terminal peptide and a cyclized N-terminal 
cysteine, and the other is dehydroalanine, which is the product of β-elimination on the 
thiocyanato group of cysteine.31  
Theoretically, the combination of chemical and enzymatic methods would be ideal 
for membrane protein digestion because small molecules can easily access cleavage sites 
within membrane proteins, and the resulting fragments would be easily accessible by 
proteases. In this work, chemical and enzymatic methods were combined to improve 
membrane protein digestion for MS analysis; chemical digestion was first performed with 
NTCB, and followed by enzymatic digestion with Glu-C or Lys-C and trypsin. These 
combinatorial digestion methods were compared to sequential enzymatic digestion with 
Lys-C and trypsin. Our experimental results confirmed that the combinatorial digestion 
method utilizing NTCB, Lys-C and trypsin was most efficient for membrane protein 
digestion. 
5.2 Experimental Methods 
5.2.1 Chemicals and reagents 
NTCB was purchased from Tokyo Chemical Industry, Co., trypsin was from 
Promega, Lysyl endopeptidase (Lys-C) was from Wako, and Endoproteinase Glu-C from 
Staphylococcus aureus was from EMD Millipore. All other reagents were purchased 
from Sigma Aldrich if not stated. Zirconia/silica beads (0.5 mm diameter) were 
purchased from BioSpec Products. HEK 293T cells were kindly provided by Dr. Gang 
Bao’s research group at the Georgia Institute of Technology. 
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5.2.2 Cell culture, lysis and membrane protein enrichment 
HEK 293T cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) 
and harvested when they reached ~80% confluency. Cell pellets were washed three times 
with PBS. To remove cytosolic proteins, digitonin buffer (150 mM NaCl, 50 mM HEPES 
(pH=7.4), 25 µg/mL digitonin, protease inhibitor (1 tablet/10 mL)) was added to the cell 
pellet and incubated with end-over-end rotation at 4 °C for ten minutes. The suspended 
cell pellet was centrifuged at 2,000 g for 10 minutes. Digitonin buffer was added to the 
cell pellet and the sample was vortexed and subsequently centrifuged at 2,000 g for 10 
minutes. This digitonin wash was repeated for a total of two washes.  
Lysis buffer (10 mM HEPES (pH=8), 1.5 mM MgCl2, 10 mM KCl) and 
zirconia/silica beads were added to the cell pellet, and placed in the Mini-Beadbeater 
(BioSpec). Samples were subjected to three 30 second cycles with 2 minutes of resting on 
ice in between. A flame-heated needle was used to poke holes in the bottom of the tubes, 
and the contents were transferred to new tubes (leaving the beads behind) through 
centrifugation at 1,000 g for 3 minutes. Samples were vortexed and centrifuged at 2,500 g 
for 5 minutes to remove cell debris. The supernatants were transferred to new tubes and 
centrifuged at 25,830 g for 30 minutes. Sodium carbonate buffer (0.1M sodium 
carbonate, 1 mM EDTA) was added to the cell pellets, vortexed, and incubated for 30 
minutes on ice. The samples were centrifuged at 25,830 g for 15 minutes, and the 
supernatant was removed. Urea buffer (75 mM NaCl, 50 mM HEPES (pH=7.4), 8 M 
urea) was added to the cell pellets and incubated with shaking for 30 minutes at room 
temperature. The samples were centrifuged at 25,830 g for 15 minutes, the supernatants 
were removed, and the urea incubation was repeated once. After the samples were 
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centrifuged and supernatants were removed, 1% SDC in PBS was added to samples to 
solubilize membrane proteins. Samples were incubated overnight with end-over-end 
rotation at room temperature. The following day, samples were centrifuged at 15,000 g 
for 15 minutes; the supernatants were transferred to new tubes and the pellets were 
discarded. Disulfide bonds within proteins were subjected to reduction by incubation with 
5 mM DTT for 25 minutes at 56 °C. The sample was then divided into three equal 
samples and transferred to 10 kDa filter columns. 
5.2.3 Lys-C and trypsin digestion 
One filter column was centrifuged at 10,000 g for 5 minutes. The alkylation 
reaction buffer (14 mM iodoacetamide, 0.1% SDS, PBS (pH=8)) was added, and the 
sample was centrifuged at 10,000 g for 5 minutes. Reaction buffer was added again and 
incubated in the dark for 20 minutes at room temperature. After incubation, the sample 
was centrifuged at 10,000 g for 5 minutes, washed with 100 mM sodium acetate (pH=5), 
centrifuged at 10,000 g for 5 minutes and rinsed with water twice. Digestion buffer (50 
mM NH4OAc, 5% ACN, 0.1 M urea) and Lys-C (enzyme:substrate ratio of ~1:100) were 
added to the sample and incubated overnight at 37 °C. The next day, trypsin was added at 
an enzyme:substrate ratio of ~1:100 and the sample was subsequently incubated for four 
hours and centrifuged at 10,000 g for 30 minutes. The flow-through was collected, and 
the filter column was washed with 50 mM ammonium bicarbonate (pH=8.5). The second 
flow-through was collected and combined with the first. Combined flow-throughs were 
acidified with TFA to a final pH of ~2, and centrifuged at 2,500 g for 5 minutes. The 
supernatant was desalted on a 50 mg tC18 SepPak cartridge and dried. Eluted peptides 
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were dissolved in 30 µL of MS solvent (5% ACN, 4% formic acid (FA)), and 4 µL were 
analyzed by LC-MS/MS. 
5.2.4 NTCB and enzymatic digestion 
The other two samples were used for combined chemical and enzymatic 
digestion. First, samples were centrifuged at 10,000 g for 5 minutes. Reaction buffer (10 
mM NTCB, 0.1% SDS, PBS (pH=8)) was added to the filter columns which were 
subsequently centrifuged at 10,000 g for 5 minutes. The buffer was added again to 
columns and incubated in the dark for 20 minutes at 40 °C, and then centrifuged at 
10,000 g for 5 minutes. Sodium acetate (100 mM, pH=5) was added to filter columns, 
which were then centrifuged at 10,000 g for 5 minutes. Filter columns were rinsed with 
water and centrifuged at 10,000 g for 5 minutes twice. Next, 50 mM ammonium acetate 
(pH=9) was added to filter columns and incubated for one hour at 50 °C. Filter columns 
were centrifuged at 10,000 g for 5 minutes and rinsed with water twice. To one filter 
column, 200 µL PBS (pH=7.4) and Glu-C (enzyme:substrate ratio of ~1:100) were 
added. To the second filter column, 200 µL digestion buffer (NH4OAc (pH=8.5), 5% 
ACN, 0.1M urea) and Lys-C at an enzyme:substrate ratio of ~1:100 were added. Both 
samples were incubated overnight at 37 °C. The next day, trypsin was added 
(enzyme:substrate ratio of ~1:100) to the Lys-C digestion sample, which was 
subsequently incubated for four hours. Both digestion samples were centrifuged at 10,000 
g for 30 minutes. The flow-through was collected for each, and filter columns were 
washed with 50 mM ammonium bicarbonate (pH=8.5). The second flow-through for each 
was collected and combined with the first. Combined flow-throughs were quenched with 
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TFA to a final pH of ~2. Acidified samples were centrifuged at 2,500 g for 5 minutes and 
the supernatant was desalted on a 50 mg tC18 SepPak cartridge and dried. Eluted 
peptides were dissolved in 30 µL of MS solvent, and 4 µL were analyzed by LC-MS/MS. 
5.2.5 LC-MS/MS analysis 
Samples were loaded onto the same HPLC as described in previous chapters, and 
peptides were separated with a 90 minute gradient of 3-25% ACN containing 0.125% 
FA. Samples were detected in the same LTQ Orbitrap Elite as described previously. 
5.2.6 Database searches 
The raw MS files were converted into mzXML format and searched using the 
SEQUEST algorithm (version 28)32 against a database that included sequences of all 
proteins in the UniProt Human (Homo sapiens) Database and common contaminants. 
FDR were estimated at the peptide level as described in previous chapters. A 20 ppm 
precursor mass tolerance and 1.0 Da product ion mass tolerance were used in the 
database search and no enzyme was specified. Samples digested with NTCB were 
searched with a parameter file listing the following differential modifications: oxidation 
of methionine (+15.9949), β-elimination of cysteine (-33.9877), cyclized N-terminal 
cysteine (+24.9952); and one fixed modification: carbamidomethylation of cysteine 
(+57.0214). The sample digested exclusively with Lys-C and trypsin was searched using 
a parameter file that listed the oxidation of methionine (+15.9949) as a differential 




5.2.7 Data filtering 
Linear discriminant analysis (LDA) was utilized to distinguish correct and 
incorrect peptide identifications as described in previous chapters. After scoring, peptides 
less than six amino acids in length were discarded and peptide spectral matches were 
filtered to a less than 1% FDR at the peptide level based on the number of decoy 
sequences in the final data set. 
5.3 Results and Discussion 
5.3.1 Peptide and protein identification 
Membrane proteins were extracted from HEK 293T cells as described above, and 
the membrane protein-enriched sample was equally split into three aliquots for 
subsequent digestion with different methods. The first sample was subjected to enzymatic 
digestion with Lys-C overnight and then trypsin for 4 hours (termed “LT” throughout this 
dissertation). Chemical and enzymatic methods were combined to perform the other 
digestions: one sample was digested with NTCB for 20 minutes and then Glu-C 
overnight (termed “NG”), and the other was digested with NTCB for 20 minutes, Lys-C 
overnight and then trypsin for 4 hours (termed “NLT”). These digested samples were 





Figure 5.1. Experimental procedure comparing three digestion methods for the 
comprehensive analysis of membrane proteins. 
 
Examples of mass spectra acquired from each digestion sample are shown in 
Figure 5.2. All three peptides are from HSPD1, a mitochondrial heat shock protein, 
which is involved in mitochondrial protein import and may play a subsequent role in the 
correct folding of imported proteins. This protein can be located in several subcellular 
components, including the extracellular region, cell surface and membrane.33 The first 














with the LT method with an XCorr of 5.1 and mass accuracy of -1.02 ppm. The second 
peptide, NAGVEGSLIVEK, identified with an XCorr of 3.5 and mass accuracy of -0.12 
ppm, was from the NLT method. The third peptide, PLVIIAEDVDGEALSTLVLNRLK, 
was digested with the NG method and identified with an XCorr of 3.8 and mass accuracy 
of -0.67 ppm. All three of these peptides have XCorr values greater than 3, which 
indicates strong correlation between the mass spectra acquired in these experiments and 
the corresponding theoretical mass spectra. Furthermore, the mass accuracy associated 
with each of these peptides was also very high (within ± 2 ppm). 
The combination of chemical and enzymatic digestion in the NLT method 
allowed the identification of 9,843 total peptides, corresponding to 2,120 proteins in the 
membrane protein-enriched sample. Among all proteins identified with the NLT method, 
1,078 or 51% were membrane proteins. Proteins were identified as membrane proteins 
through cellular component clustering analysis using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID).34-35 Just over half of the proteins 
identified were membrane proteins, which is due to the fact that complete separation of 
membrane and non-membrane proteins remains challenging.36 The work presented here 






Figure 5.2. Tandem mass spectra corresponding to peptides identified from the 
protein HSPD1 using digestion methods combining (A) Lys-C and trypsin, (B) 
NTCB, Lys-C and trypsin, and (C) NTCB and Glu-C. 
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5.3.2 Comparison of three digestion methods 
Compared to the LT method, which only utilized enzymatic digestion to identify 
7,982 peptides, 23% more peptides were identified with the NLT method, corresponding 
to 20% more proteins (1,764 proteins found with LT). In an aqueous digestion 
environment, many cleavage sites targeted by Lys-C and/or trypsin may not be accessible 
by these two proteases. However, an initial chemical digestion by NTCB cleaved proteins 
into several fragments, allowing Lys-C and/or trypsin to access the appropriate cleavage 
sites. Additionally, small molecules like NTCB can more easily access cleavage sites 
within folded membrane proteins. 
The other combinatorial digestion method employing NTCB and Glu-C (NG) 
provided the fewest number of total peptides (3,673) and proteins (1,037). Glutamic acid 
and aspartic acid are less abundant in proteins and therefore, fewer Glu-C cleavage sites 
exist; as a result, Glu-C is not as effective as Lys-C and/or trypsin. Additionally, the 
digestion efficiency of Glu-C is not as high as Lys-C and trypsin. These results are 
consistent with the fact that Lys-C and trypsin are much more frequently used in bottom-
up proteomics.  
In addition to total peptides and proteins identified, the number of membrane 
proteins identified in each experiment was also compared. The greatest number of 
membrane proteins, 1,078 proteins, was identified from the experiment that used the NLT 
method. Figure 5.3 shows the number of membrane proteins identified with each 
digestion method; a similar trend is seen among membrane proteins as total peptides and 
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proteins. All peptides identified with each digestion method are listed in a supplementary 
table online at doi.org/10.1039/C5AY00494B.  
 
 
Figure 5.3. Number of total peptides, unique peptides, proteins and membrane 
proteins identified using each digestion method. 
 
5.3.3 Peptide and protein overlap among three digestion methods 
The overlap between peptides and proteins identified with each method was also 
investigated. Figure 5.4A shows the overlap between unique peptides identified with each 
digestion method; 109 peptides were identified in all samples. There was very little 
overlap between peptides identified in samples digested with NG and either of the other 
methods (170 peptides between NG and LT, and 253 between NG and NLT), which is 
expected due to the different cleavage site specificities of each enzyme, particularly 























significant peptide overlap between the LT and NLT experiments; a total of 2,391 unique 
peptides were identified with both methods. The protein overlap between all three 
samples is shown in Figure 5.4B, and the number of proteins identified with multiple 
methods is markedly higher. Peptides from the same proteins are expected to be 
identified in multiple experiments, even if the peptides differ in sequence. More than 
70% of proteins identified in the NG experiment (773 of 1,037 proteins) were also 
identified in the NLT experiment, and 76% proteins identified with the LT method (1,341 
of 1,764 proteins) were also found with the NLT method. The overlap between 
membrane proteins identified in each method is shown in Figure 5.4C; 700 membrane 
proteins were identified in both LT and NLT experiments, and 329 proteins were found 
in all three experiments. A total of 1,308 membrane proteins were identified in this work. 
5.3.4 Missed cleavage and peptide length distributions 
Datasets were further analyzed to determine the number of missed cleavages 
associated with each digestion method (Figure 5.5A). Both methods utilizing Lys-C and 
trypsin resulted in the highest percentages of zero missed cleavages: 94% for LT and 
92% for NLT. As shown in Figure 5.5A, NG resulted in the greatest percentage of 
peptides containing missed cleavages (80% compared to 6% and 8% for LT and NLT, 
respectively), which further demonstrate that NG was not a robust digestion method. 
Although the method combining NTCB, Lys-C and trypsin gave a slightly lower 
percentage of zero missed cleavage sites compared to the LT method, 23% more total 
peptides and 20% more proteins were identified, as discussed above. Overall, the method 
combining NTCB, Lys-C and trypsin provided the most effective digestion of membrane 




Figure 5.4. Overlap between (A) peptides, (B) proteins, and (C) membrane proteins 





















































Figure 5.5. (A) Number of missed cleavages among peptides identified with each 
digestion method; (B) Distribution of peptide length for each digestion method. 
(Red: Lys-C and trypsin; Blue: NTCB, Lys-C and trypsin; Yellow: NTCB and Glu-
C). 
The length of peptides generated from each digestion method was also 
investigated. Figure 5.5B shows the peptide length distribution for each digestion 
method. There is no significant difference between methods, except that the overall 
distribution of peptide length in the NG experiment includes a greater number of larger 
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methods, the differences in peptide length typically seen between enzymatic and 
chemical cleavage could be compensated for with the sequential enzymatic methods. 
Additionally, MS is biased towards a specific peptide length range (10-30 amino acids), 
and based on the parameters used in these experiments, peptides with too few or too 
many amino acid residues may not be effectively detected. 
5.3.5 Membrane protein clustering 
Membrane proteins identified in samples digested with the NLT method were 
further studied through clustering analysis. Proteins were clustered according to 
biological process and molecular function using DAVID (Figure 5.6). Biological process 
clustering revealed that establishment of localization was most highly enriched with a P 
value of 4.5E-127. Proteins related to membrane organization and oxidation reduction 
were also highly enriched, and it is well-known that many oxidation and reduction 
reactions occur among membrane proteins in the mitochondria. A number of proteins 
with functions corresponding to cell adhesion and cell motion were also enriched. 
Molecular functions such as substrate-specific transporter activity, oxidoreductase 
activity, and protein binding were highly enriched among membrane proteins identified, 





Figure 5.6. Clustering of membrane proteins identified in the NTCB, Lys-C and 
trypsin digestion sample according to (A) biological process and (B) molecular 
function. 
 
5.3.6 SNARE complex proteins 
One specific group of membrane proteins was further investigated here. The 
soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptor (SNARE) 
complex assists in the fusion of transport vesicles with their targeted membranes.37 They 
are often found on various membranes throughout the cell, and are essential for 




















intracellular membrane trafficking. Nine proteins in this complex were identified in this 
experiment: SNAP23, STX2, STX4, STX6, STX7, STX8, STX10, STX12, and VAMP2. 
For each protein, multiple unique peptides were identified, and several examples are 
listed in Table 5.1. The greatest number of total peptides was identified with the NLT 
method (77 peptides), and notable overlap exists between the peptides identified with the 
LT and NLT methods. Fewer total peptides were identified with the NG method (22 
peptides), but they complement those identified with either the LT or NLT method. For 
example, a total of seven unique peptides were identified in the protein STX2, among 
which two peptides were identified with both the NLT and LT methods, four were 
identified with only the NLT method and one was identified with only the NG method. 
The combination of chemical and enzymatic methods demonstrated to be effective to 
analyze SNARE complex proteins, which play critical roles in membrane trafficking. All 
peptides identified from SNARE complex proteins are listed in a supplementary table 









Table 5.1. Examples of SNARE proteins and peptides identified in this work. 
Gene 
Symbol Peptide LT NLT NG 
SNAP23 
LNIGNEIDAQNPQIK    
IQQRAHQITDE    
RAHQITDESLESTR    
ILGLAIESQDAGIK    
ITNDAREDEMEENLTQVGSILGNLK    
STX2 
RSKGRIQRQLE    
AIEQSFDQDESGNR    
NDDGDTVVVVEK    
PSIFTSDIISDSQITR    
FVETQGEMINNIER    
STX4 
KNILSSADYVE    
VFVSNILKD    
EEADENYNSVNTR    
NILSSADYVER    
TQHGVLSQQFVELINK    
STX6 
MKDQMSTSSVQALAE    
LLQDPSTATREE    
AVNTAQGLFQR    
QALLGDSGSQNWSTGTTDK    
STX7 
NVENAEVHVQQANQQLSR    
FTTSLTNFQKVQRQAAE    
QLGTPQDSPELR    
NLVSWESQTQPQVQVQDEEITEDDLR    
STX8 
ALSSIISRQKQMGQE    
IIQEQDAGLDALSSIISR    
GLGFDEIR    
QNLLDDLVTR    
STX10 
ANPGKFKLPAGDLQE    
ILAGKPAAQKSPSDLLDASAVSATSRYIEE    
SPSDLLDASAVSATSR    
VSGSIQVLK    
STX12 
QSQEDEVAITEQDLELIK    
ISQATAQIK    
LMNDFSAALNNFQAVQR    
NPGPSGPQLR    
QLEADILDVNQIFK    
VAMP2 
IMRVNVDKVLE    
LSELDDRADALQAGASQFETSAAK    
ADALQAGASQFETSAAK    
LQQTQAQVDEVVDIMR    




Membrane proteins are extremely important in biological systems due to their 
involvement in a variety of cellular processes, including signal transduction, molecular 
transport, cell-cell communication and cell-environment interactions. Membrane proteins 
are notoriously difficult to analyze, even with powerful modern MS-based proteomics 
techniques, because of their hydrophobicity and overall low abundance. This work 
presents combinatorial methods incorporating chemical and enzymatic digestion to 
cleave proteins for MS analysis. Parallel experiments clearly demonstrated that the 
combination of NTCB with Lys-C and trypsin can provide 23% more total peptides and 
20% more proteins identified than the common Lys-C and trypsin digestion method. 
Chemical methods utilizing small molecules can more easily access cleavage sites within 
membrane proteins, compared to enzymatic methods which face steric hindrance. The 
combination of NTCB and Glu-C was not as effective, shown through the number of 
missed cleavages identified. Between the three digestion methods compared here, totally 
over 1,300 membrane proteins were identified. The combination of chemical and 
enzymatic methods demonstrated to be effective for membrane protein digestion, and 
further implementation of this method will allow the comprehensive and quantitative 
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CHAPTER 6. CONCLUSIONS AND FUTURE OUTLOOK 
6.1 Mass spectrometric analysis of the cell surface N-glycoproteome 
6.1.1 Summary of results 
Cell surface N-glycoproteins play extraordinarily important roles in cell-cell 
communication, cell-matrix interactions and cellular response to environmental cues. 
Global analysis is exceptionally challenging because many N-glycoproteins are present at 
low abundances and effective separation is difficult to achieve. Here we have developed a 
novel strategy integrating metabolic labeling, copper-free click chemistry and MS-based 
proteomics methods to analyze cell surface N-glycoproteins comprehensively and site-
specifically. A sugar analogue containing an azido group, N-azidoacetylgalactosamine, 
was fed to cells to label glycoproteins. Glycoproteins with the functional group on the 
cell surface were then bound to dibenzocyclooctyne-sulfo-biotin via copper-free click 
chemistry under physiological conditions. After protein extraction and digestion, 
glycopeptides with the biotin tag were enriched by NeutrAvidin conjugated beads. 
Enriched glycopeptides were deglycosylated with PNGase F in heavy-oxygen water, and 
in the process of glycan removal, asparagine was converted to aspartic acid and tagged 
with 18O for MS analysis. 
With this strategy, 144 unique N-glycopeptides containing 152 N-glycosylation 
sites were identified in 110 proteins in HEK 293T cells. As expected, 95% of identified 
glycoproteins were membrane proteins, which were highly enriched. Many sites were 
located on important receptors, transporters, and CD proteins. The experimental results 
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demonstrated that the current method is highly effective for the comprehensive and site-
specific identification of the cell surface N-glycoproteome and can be extensively applied 
to other cell surface protein studies. 
6.1.2 Future directions 
The method presented here provides the foundation for a variety of cell surface 
glycoprotein studies. One of the main advantages of this method is that metabolic 
labeling and the click reaction to tag surface glycoproteins is performed under 
physiological conditions, allowing broad applications for investigating surface 
glycoprotein response to different stimuli. It can be applied extensively to 
comprehensively investigate surface glycoproteins in cultured cells or animal models, 
including mice and zebrafish. One general application is to investigate changes in surface 
glycoproteins as a result of drug treatment, including inhibitors or other stimuli. An 
example of this application is presented in Chapter 3, by pairing this method with 
quantitative proteomics to identify and quantify cell surface N-glycoproteins throughout 
epithelial-mesenchymal transition. Global analysis of cell surface glycoproteins will 
provide a catalog of proteins from which biomarkers and drug targets can be identified. 
Glycosylation site occupancy can also be exploited to gain a better understanding of 
cellular mechanisms related to disease and development. 
6.2 Quantification of cell surface N-glycoproteome throughout epithelial-
mesenchymal transition 
6.2.1 Summary of results 
 134 
 
By coupling TMT labeling with our cell surface N-glycoprotein method described 
in Chapter 2, surface glycoprotein abundance changes were quantified in MCF 10A cells 
undergoing the epithelial-mesenchymal transition. MCF 10A cells were treated with 
TGF-β to induce EMT, and cells were sampled at varying times (0, 4 and 8 days) to 
determine surface glycoprotein abundance changes throughout the transition. A total of 
438 unique glycopeptides corresponding to 235 glycoproteins were quantified: 39 were 
down-regulated and 37 were up-regulated throughout EMT. Abundance changes 
throughout EMT were also investigated at the protein level: 4656 proteins were 
quantified, including 534 down-regulated and 699 up-regulated. Interestingly, down-
regulated proteins were very highly enriched with biological processes associated with 
ribonucleoprotein complex biogenesis (P = 2.98E-62) and molecular functions related to 
RNA binding (P = 7.69E-87), implying that translation may be modulated during EMT. 
Up-regulated proteins were highly enriched with transport and oxidation-reduction 
processes. These results provide insight into the correlation between surface 
glycosylation and the molecular mechanisms of EMT. 
6.2.2 Future directions 
While the current results show interesting abundance changes in surface 
glycoproteins throughout EMT, the conclusions are somewhat limited by the time points 
studied. Further experiments can investigate more time points throughout the transition, 
to gain a more thorough understanding of when and how surface glycoprotein 
expressions change. To confirm the current results, the reverse process, mesenchymal to 
epithelial transition, can be induced and glycoprotein abundances can be compared. 
Based on the results that the majority of surface glycoproteins are not consistently up- or 
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down-regulated throughout EMT, future work can study the glycan structures and how 
they vary during the same time points. Since the glycans on these glycoproteins are the 
main players involved in extracellular interactions, it is possible that their structures and 
abundances are more dynamic than the proteins themselves. Investigating surface 
glycoprotein changes throughout EMT will provide a better understanding of the 
mechanisms of this transition and insight into how glycosylation and protein expression 
is modulated during the transition. Determining surface proteins that change in specific 
cancer or diseased cells may lead to the discovery of drug targets that would inhibit 
mesenchymal cell formation. 
6.3 Global analysis of secreted proteins and glycoproteins in Saccharomyces 
cerevisiae 
6.3.1 Summary of results 
Protein secretion is essential for numerous cellular activities, and secreted 
proteins in bodily fluids are a promising and non-invasive source of biomarkers for 
disease detection. Systematic analysis of secreted proteins and glycoproteins will provide 
insight into protein function and cellular activities. Yeast (Saccharomyces cerevisiae) is 
an excellent model system for eukaryotic cells, but global analysis of secreted proteins 
and glycoproteins in yeast is challenging due to the low abundances of secreted proteins 
and contamination from high-abundance intracellular proteins. Here, by using mild 
separation of secreted proteins from cells, we comprehensively identified secreted 
proteins and glycoproteins and quantified their abundance changes through inhibition of 
protein glycosylation and MS-based proteomics. 
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In biological triplicate experiments, 245 secreted proteins were identified, and 
comparison with previous experimental and computational results demonstrated that 
many identified proteins were located in the extracellular space. The majority of 
quantified secreted proteins were down-regulated from cells treated with an N-
glycosylation inhibitor (tunicamycin). The quantitative results strongly suggest that the 
secretion of these down-regulated proteins was regulated by glycosylation while, the 
secretion of proteins with minimal abundance changes was contrarily irrelevant to protein 
glycosylation, likely being secreted through non-classical pathways. Glycoproteins in the 
yeast secretome were globally analyzed for the first time. A total of 27 proteins were 
quantified in at least two protein and glycosylation triplicate experiments, and all except 
one were down-regulated under N-glycosylation inhibition, which is solid experimental 
evidence to further demonstrate that the secretion of these proteins is regulated by their 
glycosylation. These results provide valuable insight into protein secretion, which will 
further advance protein secretion and disease studies. 
6.3.2 Future directions 
This work provides preliminary information regarding protein secretion and its 
regulation by glycosylation. There are many avenues to pursue an in-depth understanding 
of this relationship, including beginning to distinguish between classical and non-
classical secretion. Currently, the mechanisms behind non-classical secretion are 
ambiguous, which makes the differentiation of classical and non-classical secretion 
difficult in this study. One approach includes using another drug or inhibitor to prevent 
non-classical secretion to validate the group of proteins identified here that are believed 
to be secreted via non-classical pathways. Furthermore, glycan structures and maturity 
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can be investigated to determine how the glycan modifications are impacted when 
secretion is blocked. Treating cells with castanospermine, a glucosidase inhibitor, will 
limit N-glycan trimming and subsequently prevent glycan structures from reaching their 
correct final structure. These results may reveal specific structures that induce or prevent 
glycoprotein trafficking and secretion.  Understanding protein secretion on a 
comprehensive scale will provide critical information regarding cellular processes.  
Furthermore, secreted proteins in bodily fluids represent a promising source of non-
invasive biomarkers for disease detection and surveillance. 
6.4 Enhancing the mass spectrometric identification of membrane proteins  
6.4.1 Summary of results 
Membrane proteins are critical for many cellular events, including cell signaling, 
molecular transport, and extracellular interactions. One third of the genome is estimated 
to encode membrane proteins, which are correlated with disease progression and can 
serve as promising biomarkers and drug targets. Modern MS-based proteomics 
techniques facilitate the global analysis of proteins in complex biological samples; 
however, the hydrophobicity of membrane proteins inhibits their comprehensive analysis. 
Since membrane proteins are not easily accessible by proteases in aqueous solutions, a 
combinatorial method incorporating chemical and enzymatic digestion is presented here 
to improve the membrane protein digestion for MS analysis. Chemical digestion with 2-
nitro-5-thiocyanatobenzoic acid (NTCB) was supplemented with enzymatic digestion 




Three parallel experiments were performed with membrane protein extracts from 
HEK 293T cells, and the results demonstrated that combining NTCB with Lys-C and 
trypsin resulted in the greatest number of total peptides (9,483 peptides). Comparatively, 
digestion with only Lys-C and trypsin allowed the identification of 7,982 total peptides, 
and sequential digestion with NTCB and Glu-C resulted in 3,673 peptides. By integrating 
chemical digestion before enzymatic digestion, NTCB could more easily access cleavage 
sites within membrane proteins, and the resulting peptide fragments were thus more 
accessible by proteases. The combination of chemical and enzymatic digestion presented 
here proved to be effective for membrane protein analysis. 
6.4.2 Future directions 
Combining chemical and enzymatic digestion increased the MS-based 
identification of membrane proteins compared to common enzyme-only digestion. 
However, the scope of this work could be expanded to include more proteases and 
chemicals to further optimize digestion. The overall workflow could be simplified 
through use of different chemical digestion, such as cyanogen bromide (CNBr), which 
does not require protein reduction prior to digestion. However, this may be at the cost of 
lower membrane protein identification, and should be investigated. This method can also 
be applied to membrane and surface glycoprotein studies, to enhance the proteome 
coverage. Improved membrane protein identification by mass spectrometry can be 




APPENDIX A. COLLABORATIVE RESEARCH 
This appendix briefly describes collaborative projects completed in conjunction with 
the work presented in this dissertation. Collaborations outside of the Wu group are 
described first, followed by collaborative projects within the Wu group. 
A.1 Competitive protein binding influences heparin-based modulation of spatial 
growth factor delivery for bone regeneration 
Reproduced with permission from Mary Ann Liebert, Inc. publishers 
Hettiaratchi, M.H., Chou, C., Servies, N., Smeekens, J.M., Cheng, A., Essancy, C., Wu, 
R., McDevitt, T.C., Guldberg, R.E., Krishnan, L. Competitive protein binding influences 
heparin-based modulation of spatial growth factor delivery for bone regeneration, Tissue 
Engineering Part A, 2017, DOI:10.1089/ten.TEA.2016.0507. Copyright 2017 Mary Ann 
Liebert, Inc. 
 
A.1.1  Summary of project 
Tissue engineering strategies involving the in vivo delivery of recombinant 
growth factors are often limited by the inability of biomaterials to spatially control 
diffusion of the delivered protein within the site of interest. The poor spatiotemporal 
control provided by porous collagen sponges, which are used for the clinical delivery of 
bone morphogenetic protein-2 (BMP-2) for bone regeneration, have necessitated the use 
of supraphysiological protein doses, leading to inflammation and heterotopic ossification. 
This study describes a novel tissue engineering strategy to spatially control rapid BMP-2 
diffusion from collagen sponges in vivo by creating a high affinity BMP-2 sink around 
the collagen sponge. We designed an electrospun polycaprolactone nanofiber mesh 
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containing physically entrapped heparin microparticles, which have been previously 
demonstrated to bind and retain large amounts of BMP-2. Nanofiber meshes containing 
0.05 and 0.10 mg of microparticles/cm2 demonstrated increased BMP-2 binding and 
decreased BMP-2 release in vitro compared to meshes without microparticles. However, 
when microparticle-containing meshes were used in vivo to limit diffusion of BMP-2 
delivered using collagen sponges in a rat femoral defect, no differences in heterotopic 
ossification or biomechanical properties were observed. Further investigation revealed 
that, although BMP-2 binding to heparin microparticles was rapid, the presence of serum 
components attenuated microparticle-BMP-2 binding and increased BMP-2 release in 
vitro. These observations provide a plausible explanation for the results observed in vivo 
and suggest that competitive protein binding in vivo may hinder the ability of affinity-
based biomaterials to modulate growth factor delivery.  
A.1.2  MS-based proteomics contributions 
In order to identify serum proteins bound to microparticles, mass spectrometry 
analysis was performed on microparticles (1 mg) loaded with 5 mL of FBS or 5 mL of 
FBS and 8 μg BMP-2 together. The microparticles were centrifuged, washed once with 
PBS, and proteins bound to microparticles were digested with 2 units of glutamyl 
endopeptidase (Glu-C) for 16 hours and 10 units of lysyl endopeptidase (Lys-C) for 3.5 
hours in 50 mM HEPES (pH=7.9). Eluted peptides were purified, dried, and resuspended 
in a 5% acetonitrile and 4% formic acid solution for LC-MS/MS analysis.  
Mass spectrometry was used to identify serum proteins on FBS-loaded heparin 
microparticles. Proteins identified based on only two or fewer unique peptides were 
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excluded from the analysis. Out of 33 total proteins identified, 20 were known heparin-
binding proteins, including several apolipoproteins and thrombospondins. Selected 
peptides identified from these heparin-binding proteins are highlighted in Table A.1. 
XCorr signifies the correlation between the experimental mass spectra and theoretical 
mass spectra of the peptide, while the mass accuracy of each peptide demonstrates how 
closely the theoretical mass of the peptide matches the experimentally measured mass.  
 
Table A.1. Selected peptides from known heparin binding proteins identified on 
FBS-loaded heparin microparticles. 
Protein Peptide ppm XCorr 
Apolipoprotein-A1 
 
NWDTLASTLSK 1.03 3.3 
 
TLRQQLAPYSDD 0.63 2.9 
 
QLGPVTQE 0.27 2.6 
Apolipoprotein-B TSRSLPYAQNIQDQLSGLQE 1.30 5.9 
 
VSDSLIGVTQGYSVTVK -0.28 4.5 
 
ITVPASQLTVSQFTLPK 0.77 4.1 
Apolipoprotein-C2 TYLPAVDEK 0.55 2.4 
 
QVFSVLSGKD 0.71 2.0 
 
SLLGYWDTAK 0.83 2.9 
Apolipoprotein-E LQAAQARLGSDME 0.64 4.6 
 
YLRWVQTLSDQVQE -0.06 4.3 
 
QGQSRAATLSTLAGQPLLE 0.73 3.8 
Thrombospondin-1 DHSGQVFSVISNGK -0.37 4.8 
 
FQDLVDAVRAE 0.45 3.6 
 
GPDPSSPAFRIE 0.83 3.1 
Thrombospondin-4 FQTQNFDRLD -0.13 2.4 
 
SSATIFGLYSSADHSK 0.70 2.3 
 
SSATIFGLYSSADHSK 0.04 3.8 
Fibronectin-1 LGVRPSQGGEAPRE 0.62 4.4 
 











The extracellular matrix protein fibronectin, which has a known heparin binding 
site and specific affinity for heparin, was confidently identified based on 26 unique 
peptides.1 On microparticles loaded with both FBS and BMP-2, BMP-2 was only 
identified based on one unique peptide and thus was not included in the list of detected 
proteins. This further suggests that FBS borne proteins bound to the microparticles in 
larger quantities than BMP-2 and corroborates the results obtained from SDS-PAGE 
analysis. 
A.2 Yeast rRNA Expansion Segments: Folding and Function 
Reproduced with permission from Elsevier 
Gómez Ramos, L.M., Smeekens, J.M., Kovacs, N.A., Bowman, J.C., Wartell, R.M., Wu, 
R., Williams, L.D. Yeast rRNA expansion segments: Folding and function, Journal of 
Molecular Biology, 2016, 428 (20), 4048-4059. Copyright 2016 Elsevier. 
 
A.2.1  Summary of project 
Divergence between prokaryotic and eukaryotic ribosomal RNA (rRNA) and 
among eukaryotic ribosomal RNAs is focused in expansion segments (ESs). Eukaryotic 
ribosomes are significantly larger than prokaryotic ribosomes partly because of their ESs. 
We hypothesize that larger rRNAs of complex organisms could confer increased 
functionality to the ribosome. Here, we characterize the binding partners of 
Saccharomyces cerevisiae expansion segment 7 (ES7), which is the largest and most 
variable ES of the eukaryotic large ribosomal subunit and is located at the surface of the 
ribosome. In vitro RNA‐protein pull-down experiments using ES7 as a bait indicate that 
ES7 is a binding hub for a variety of non-ribosomal proteins essential to ribosomal 
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function in eukaryotes. ES7-associated proteins observed here cluster into four groups 
based on biological process, (i) response to abiotic stimulus (e.g., response to external 
changes in temperature, pH, oxygen level, etc.), (ii) ribosomal large subunit biogenesis, 
(iii) protein transport and localization, and (iv) transcription elongation. Seven 
synthetases, Ala-, Arg-, Asp-, Asn-, Leu-, Lys- and TyrRS, appear to associate with ES7. 
Affinities of AspRS, TyrRS and LysRS for ES7 were confirmed by in vitro binding 
assays. The results suggest that ES7 in S. cerevisiae could play a role analogous to the 
multi-synthetase complex present in higher order organisms and could be important for 
the appropriate function of the ribosome. Thermal denaturation studies and footprinting 
experiments confirm that isolated ES7 is stable and maintains a near-native secondary 
and tertiary structure. 
A.2.2  MS-based proteomics contributions 
S. cerevisiae cell lysates were screened for proteins with affinity for ES7 using 
pull-down assays. Briefly, isolated ESs, or fragments of ESs, were attached to beads, 
incubated with cell lysates and washed to remove non-specific and weakly associated 
proteins. The remaining ES-associated proteins were proteolytically digested and the 
resulting peptides were identified by LC-MS/MS and analyzed by tandem mass spectra. 
During exponential growth of S. cerevisiae, 36 proteins were seen to interact with ES7. 
Our assay identifies primary proteins that interact directly with ES7 in addition to 
secondary proteins that bind to the primary proteins. We attached isolated ES7 to beads, 
incubated the beads with cell lysates, washed the beads to remove non-specific and 
weakly associated proteins, and then proteolytically digested the ES7-associated proteins. 
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Many of the proteins seen here to associate with ES7 have been previously shown 
to bind to the ribosome. Of the 36 ES7-associated proteins here, 25 were identified by 
Link as components of intact translation complexes.2 These proteins include aspartyl 
tRNA synthetase (AspRS), translation machinery-associated protein 10 (TMA10), 
ribosome biogenesis protein ERB1 and ATP-dependent RNA helicase MAK5. Of these, 
12 of them were identified as mRNA-binding proteins (mRBPs) by Hentze.3 Nine 
proteins that associate with ES7 in this work were previously found to associate both with 
intact ribosomes and with mRNA.2-3 Those nine are (i) protein transport factor SEC1; (ii) 
MAK21, which is involved in maturation and export of pre-LSU particles; (iii) fimbrin, 
which is an actin-bundling protein involved in cytoskeleton organization and 
maintenance; (iv) HXK1, which catalyzes hexose phosphorylation; (v) NAD(+) salvage 
pathway component, nicotinamidase; (vi) transcription elongation factor SPT6; (vii) 
AspRS; (viii) 40S ribosomal protein S30; and (ix) protein PBI2, inhibitor of vacuolar 
protein B. 
Seven aminoacyl tRNA synthetases (aaRSs) were identified here in association 
with ES7. AspRS and tyrosyl tRNA synthetase (TyrRS) were found in each of the 
replicate experiments. Cumulatively Ala-, Arg-, Asn-, Asp-, Leu-, Lys- and TyrRS were 
observed in at least one experiment. Our observations are consistent with Link et al., who 
observed Ala-, Asn-, Asp-, Leu- and LysRS bound to intact ribosomes.2 AspRS, LeuRS, 
and LysRS associate more tightly with the intact ribosome than AlaRS and AsnRS. The 




A total of six proteins known to localize in the nucleolus are observed here to 
associate with ES7.4 Nucleolar proteins that associate with ES7 include (i) MAK5, (ii) 
MAK21, (iii) ERB1, (iv) ribosome biogenesis ATPase RIX7, (v) DNA-directed RNA 
polymerase I subunit RPA49 and (vi) RNA 3′-terminal phosphate cyclase-like protein 
RCL1. 
Clustering of ES7-associated proteins by biological process was performed using 
the Database for Annotation, Visualization and Integrated Discovery (DAVID). Four 
clusters are highly enriched (Figure A.1 and Table A.2), including (i) response to abiotic 
stimulus such as temperature, (ii) ribosomal LSU biogenesis, (iii) protein transport and 
localization, and (iv) transcription elongation. For this analysis, if multiple clusters 
contained identical proteins, only the cluster with the lowest P-value was retained. The 
two most intense clusters correspond to response to abiotic stimulus (P = 5.3 × 10−3) and 
ribosomal LSU biogenesis (P = 1.03 × 10−2). With DAVID we were unable to cluster all 
36 ES7-associated proteins because the functional annotation for the S. cerevisiae 
proteome is not fully finalized in the database. Of the 36 ES7-associated proteins, 12 
were not clustered. Six mitochondrial proteins observed were assumed to be artifacts and 
were excluded from the analysis. 
For comparison, we clustered Hentze's mRBPs by the same methods we used here 
for ES7-associated proteins, and we observed some of the same clusters. Clusters 
common to mRBPs and ES7-associated proteins include (i) response to abiotic stimulus 
and (ii) protein transport and localization. ES7-associated proteins were also clustered 
based on molecular function with DAVID (Figure A.1 and Table A.2). These results 
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demonstrate that ES7-associated proteins are important in (i) nucleotide binding and (ii) 
catalytic activity. Both of these clusters are also seen in mRBPs. 
 
Figure A.1. Clustering of S. cerevisiae ES7-associated proteins identified in this 
work, based on biological process and molecular function. 
 
Table A.2. List of genes included in each cluster in Figure A.1. 
Biological Process Genes 
Response to abiotic stimuli SEC1, PBS2, PBI2, SAC6, HXK1, TMA10, BDH1, 
PNC1 
LSU rRNA biogenesis MAK5, RIX7, ERB1, MAK21 
Transcription elongation SPT6, CHD1, CTR9 
Protein transport and 
localization 
NUM1, SEC1, PBS2, RIX7, YHB1, HXK1, YRB1, 
RTS1, YGR130C, VMA5, PEP8, SAC6, PBI2, SEC17 
Molecular Function Genes 
Nucleotide binding VMA5, MAK5, RIX7, PBS2, CHD1, HXK1, TYS1, 
DPS1, MET5, ERG1 
Catalytic activity MAL32, MAK5, PBS2, RIX7, SPT6, YHB1, HXK1, 
TYS1, PNC1, DPS1, ERG1, RTS1, RCL1, RPA49, 




A.3 Elongated expansion segments extend the capabilities of human ribosomes 
Reproduced from 
Gómez Ramos, L.M., Smeekens, J.M., Kovacs, N.A., Fang, P.Y., Petrov, A.S., Bernier, 
C.R., Hu, M., Bowman, J.C., Wartell, R.M., Wu, R., Williams, L.D. Elongated expansion 
segments extend the capabilities of human ribosomes. Submitted. 
 
A.3.1  Summary of project 
Metazoan ribosomes are elaborated by large expansion segments, which contain 
long unbranched helices marked by numerous bulges and mismatches. This work 
investigates the functions of the largest expansion segments (ESs) of the human ribosome 
using pull-down assays analyzed by mass spectroscopy. Human ESs associate with a 
variety of critical proteins including members of the ubiquitin-proteasome system. The 
results suggest that protein synthesis is physically coupled with protein degradation in 
humans. A variety of other functional proteins associate with ESs, including proteins 
involved in transcription, translation, signaling and structure. The distribution of ES-
associated proteins is different for a non-carcinoma and a carcinoma cell line. We 
characterize the stability, secondary structure and in vitro folding of the largest human 
ES. Human ESs contain sequences with G-scores > 38 suggestive of potential G-
quadruplexes. Some single-stranded ES fragments show K+-dependence of circular 
dichroism spectra, characteristic of G-quadruplex formation.  
A.3.2  MS-based proteomics contributions 
A.3.2.1  Protein binding to human rRNA expansion segments 
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The goal here is to characterize interactions between human ES rRNAs and 
human proteins. Human cell lysates were screened to identify proteins and protein 
complexes that associate with ES7 and ES27. To determine if protein-rRNA interactions 
differ based on cell line, multiple cell lines were investigated. The two cell lines 
investigated here are a non-carcinoma cell line (HEK 293T) and a metastatic carcinoma 
cell line (MDA-MB-231). The assay here does not distinguish primary proteins, which 
bind directly to ES rRNAs, from secondary proteins, which bind to primary proteins. 
Some of the proteins observed here in association with ESs are known to interact with 
each other in vivo suggesting secondary association. 
Isolated ESs, or fragments of ESs, were attached to beads, incubated with cell 
lysates and washed to remove non-specific and weakly associated proteins. The 
remaining ES-associated proteins were proteolytically digested and the resulting peptides 
were identified by LC-MS/MS and analyzed by tandem mass spectra. ES-associated 
proteins were clustered based on biological process and/or molecular function with 
DAVID. Control experiments characterizing interactions of human proteins with an ES 
from a fungi (designated ES7SC) were also performed. 
For each rRNA fragment, four replica experiments were performed with each cell 
line. The proteins detected were partitioned into Groups (called Group I and II) based on 
the stringency of the result. Group I contains proteins observed in all four replica 
experiments, which are identified with the greatest confidence and appear to bind with 
the greatest affinity. Group II contains proteins observed in two or three of the four 
replica experiments, that appear to bind to the ESs with lower affinity or more transiently 
than Group I proteins. The groups associated with HEK 293T cells are indicated with a 
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subscript H (i.e. Group IH). The groups associated with MDA-MB-231 cells are indicated 
with a subscript M (i.e. Group IM). In general, more proteins were identified in Groups IH 
than in Groups IM. 
A.3.2.2  Human ESs associate with the UPS 
Many proteins of the ubiquitin-proteasome system (UPS) bind to human ESs. The 
amount of interaction depends on both the identity of the ES and on the cell line. 
Interactions with the UPS are more extensive for ES7 than for ES27, and are more 
extensive in HEK 293T cells than in MDA-MB-231 cells. The differences between cell 
lines are consistent with the abundance of UPS-proteins, which is known to depend on 
cell line and is higher in HEK 293T than in other cell lines tested.5-6 Differences in 
protein affinity between ESs are not totally unexpected because ESs have distinctive 
sequences and structures. 
The results here suggest that components of the UPS have specific affinity for 
ES7 and lower, non-specific affinity for general rRNAs. Sixty percent of proteins in 
Group IES7,H (9 out of 15) and 12% in Group IES27,H (2 out of 16) are known to be 
involved in ubiquitination or sumoylation processes. No Group IES7,M and Group IES27,M 
proteins are involved in the UPS. Group II proteins, which are thought to bind with low 
affinity, exhibit a more uniform distribution of UPS proteins over cell line and ES than 
that observed for Group I. UPS proteins constitute 6% of Group IIES7,H (12 out of 203), 
5% of Group IIES27,H (12 out of 261), 7% of Group IIES7,M (12 out of 170) and 5% of 
Group IIES27,M (10 out of 182).  
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The results suggest that the UPS associates with ES7 in HEK 293T cells. Group 
IES7,H contains a broad range of UPS proteins including enzymes involved in activation 
(E1), conjugation (E2) and ligation (E3) of ubiquitin, as well as known protein binding 
partners of ligase and deubiquitinating enzymes. Group IES7,H contains three E1-like 
enzymes, SUMO-activating enzyme subunit 2 (SAE2), NEDD8-activating enzyme E1 
regulatory subunit (ULA1) and Ubiquitin-like modifier-activating enzyme 5 (UBA5) and 
a E2 ubiquitin-conjugating enzyme, E2O (UBE2O). E2O is a hybrid of E2 and E3 
activities. This Group also contains several proteins that bind to deubiquitinating 
enzymes, including transcription elongation factor A protein-like 4 (TCAL4), Ankyrin 
repeat domain-containing protein 17 (ANR17) and Nucleoside diphosphate kinase A 
(NME1).7 CD2 antigen cytoplasmic tail-binding protein 2 (CD2B2) is a protein-binding 
partner for E3-ligase NEDD4 and Neurofilament light polypeptide (NFL) interacts with 
E3 SUMO-protein ligase PIAS4.8-9 Group IES7,H contains both, CD2B2 and NFL.  
Unlike Group I, the proteins identified in Groups II are similar for both cell lines. 
Group IIES7,H include the 26S proteasome non-ATPase regulatory subunits 7 and 14, 
Ubiquitin carboxyl-terminal hydrolases 10 and 14, NEDD8-activating enzyme E1 
catalytic subunit, Proteasome subunit beta type-7 and COP9 signalosome complex 
subunit 7a. Similarly, Group IIES7,M proteins include 26S proteasome non-ATPase 
regulatory subunit 8, Ubiquitin carboxyl-terminal hydrolase 4, NEDD8-activating 
enzyme E1 regulatory subunit, Proteasome subunit alpha type-2,4 and 6 and COP9 
signalosome complex subunit 5. 
Specific interactions of UPS components are attenuated in ES27 compared to 
ES7. No proteins in Group IES27,M are involved in the UPS. Only two Group IES27,H 
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proteins are involved in the UPS. These two proteins are ubiquitin carboxyl-terminal 
hydrolase 7 (UBP7) and TIF1A, which has dual functionality and is involved in both 
transcription and protein degradation.10-12 Group IIES27,H proteins include Ubiquitin-like 
modifier-activating enzyme 1, Ubiquitin-conjugating enzyme E2T, SUMO-activating 
enzyme subunit 1 and 26S proteasome non-ATPase regulatory subunit 10. Group IIES27,M 
proteins include Ubiquitin-like modifier-activating enzyme 6, Ubiquitin-conjugating 
enzyme E2C, SUMO-activating enzyme subunit 2 and NEDD8-activating enzyme E1 
regulatory subunit. 
Control experiments were performed with ES7SC (ES7 from S. cerevisiae) and 
HEK 293T cells. ES7SC differs from human ES7 in sequence and composition. ES7SC is 
smaller than ES7 in human although structurally the branching core is conserved. For 
ES7SC, only 14% of proteins in Group I (1 out of 7) and 8% in Group II (14 out of 169) 
are related to the UPS. These results are in contrast with those obtained for human ES7 
(Group IES7,H) in which 60% of the proteins are related to the UPS. In previous work, 
UPS components in S. cerevisiae cell extracts were not observed to associate with 
ES7SC.13 
A.3.2.3  Ribosomal proteins 
Ribosomal proteins have at least some non-specific affinity for rRNA. However, 
ribosomal proteins that are not contained in assembled ribosomes are quickly degraded 
and are present at low levels in the cytosol.14-15 Thus, we anticipated that even though 
ribosomal proteins are highly abundant in cells, they would not be accessible, and would 
not be identified in our experiments. Indeed, we observe only a single ribosomal protein 
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with high confidence. Ribosomal protein SA is observed in Group IES7,M. SA has multiple 
functions and is known to be present outside of ribosomes in the cytosol, in the plasma 
membrane and the in nucleus.16 Except for L35, which is seen in both Group IIES7,H and 
Group IIES27,H, there is no overlap between ribosomal proteins in various subsets of 
Group II. Group IIES7,H contains ribosomal proteins L6, L12, L35, L38, S4, S14, S21, S23 
and S25. Group IIES27,H contains L7, L17, L31, L35, S2, S12 and S24. Group IIES7,M 
contains L13a, L28, L36a and S19. Group IIES27,M contains 60S acidic ribosomal protein 
P0, S6, S8, S24, S17 and S23. L6, L13a and L28 are among those that associate with ESs 
in the assembled ribosome.17 
A.3.2.4  G-quadruplex associated proteins 
 Several proteins with known affinity for RNA G-quadruplexes were observed in 
Groups II. These proteins include RNA binding protein 14, ribosomal proteins L6, L7, 
L12, S2 and S6, and serine/arginine-rich splicing factors 1 and 9.18 In addition, Fragile X 
mental retardation protein 1 (FMR1) and Fragile X mental retardation syndrome-related 
protein 1 (FXR1), which associates directly with FMR1, were also identified.19-21  
A.3.2.5  Other ES7-associated proteins 
 Group IES7,H contains proteins involved in transcription and translation. These 
proteins include TCAL4 and Eukaryotic peptide chain release factor subunit 1 (ERF1). 
TCAL4 was discussed in the section above as a binding partner for proteins associated 
with ubiquitination. Group IES7,H contains a kinase, an ATPase, a nucleoside catabolic 
enzyme, a protein involved in RNA splicing and a structural protein. Group IES7,M 
proteins differ from those of Group IES7,H in that Group IES7,M includes more proteins 
 153 
 
involved in RNA processing. There are four proteins involved in mRNA processing 
within Group IES7,M and one involved in transcription regulation. 
 For ES7, the functional classes of proteins are generally similar in Group I. Both 
Group IIES7,H and Group IIES7,M contain proteins involved in transcription, translation, 
mRNA splicing, signaling and structure. Group IIES7,H, in comparison to Group IIES7,M, 
contains more translation initiation factors and signaling proteins. Group IIES7,H contains 
some proteins that are not observed in Group IIES7,M, including seryl-aminoacyl tRNA 
synthetase and several proteins involved in ribosomal biogenesis. Association of 
aminoacyl tRNA synthetases with ES7 was previously observed in S. cerevisiae.13 Some 
Group II proteins may reflect weak secondary interactions between other Group II 
proteins. An example is given by eukaryotic initiation factor 4E (EIF4E) and Fragile X 
mental retardation protein (FMR1), found in Group IIES7,H. A complex formed by FMR1, 
EIF4E and additional proteins inhibits translation initiation in neurons.22 These 
observations reinforces that our experiments identify primary as well as secondary 
proteins. 
A.3.2.6  Clustering of ES7-associated proteins 
Clustering of ES-associated proteins was performed based on molecular function 
or biological process using DAVID (Figure A.2). Group IES7,H shows four biological 
process clusters. These clusters are (i) protein catabolic processes, (ii) metabolic 
processes, (iii) ribonucleoside triphosphate biosynthetic processes and (iv) cellular 




Group IES7,M shows three biological process clusters, (i) RNA processing, (ii) 
gene expression and (iii) cellular process. Clustering Group IES7,M by molecular function 
gives only a single cluster, which is protein binding. As described previously, if an 
identical group of proteins is assigned to multiple clusters, we consider only the cluster 
with the lowest P-value.13 
 
 
Figure A.2. Clustering of human ES7- and ES27-associated proteins obtained from 
pull-down experiments with HEK 293T and MDA-MB-231 cells based on biological 
process and molecular function. Clustering of proteins of (A) Group IES7,H, (B) 
Group IES7,M, (C) Group IES27,H, and (D) Group IES27,M. Clusters by biological 
process were not obtained for Group IES27,H and Group IES27,M. 
 
A.3.2.7  Other ES27-associated proteins 
As with ES7, ES27 rRNA associates with proteins involved in RNA processing, 
transcription, translation and structure. Group IES27,H contains many RNA binding 
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proteins and structural proteins. Group IES27,M also include proteins involved in 
transcription, translation and RNA splicing. 
As with ES7, in ES27 the distribution of Groups II proteins is generally similar to 
the distribution observed for Group I proteins. In fact, many protein categories identified 
here for ES27 were also identified in Groups II for ES7. Both, Group IIES27,H and Group 
IIES27,M, contain proteins involved in transcription, translation, structure and signaling. 
Group IIES27,H contains a significant amount of structural proteins, several ATPases, 
GTPases, kinases, transcription factors, translation initiation factors, translation 
elongation factors, some splicing factors, a couple of ribosome biogenesis proteins, 
aminoacyl tRNA synthatases and RNA helicases. Although the composition of Group 
IIES27,M is similar to that of Group IIES27,H, this group contains more translation initiation 
factors and aminoacyl tRNA synthetases, and lacks of proteins directly involved in RNA 
splicing, ribosome biogenesis, translation elongation factors and RNA helicases.  
A.3.2.8  Clustering of ES27-associated proteins 
Group IES27,H and Group IES27,M (Figure A.2C and D) failed to cluster by 
biological process. Molecular function of HEK 293T proteins yielded two clusters, (i) 
poly-pyrimidine tract binding and (ii) RNA binding. Clustering of MDA-MB-231 






A.4 A universal chemical enrichment method for mapping the yeast N-
glycoproteome by mass spectrometry 
Reproduced with permission from the American Society for Biochemistry and Molecular 
Biology 
Chen, W., Smeekens, J.M., Wu, R. A universal chemical enrichment method for mapping 
the yeast N-glycoproteome by mass spectrometry (MS), Molecular & Cellular 
Proteomics, 2014, 13, 1563-1572. Copyright 2014 American Society for Biochemistry 
and Molecular Biology. 
 
Glycosylation is one of the most common and important protein modifications in 
biological systems. Many glycoproteins naturally occur at low abundances, which makes 
comprehensive analysis extremely difficult. Additionally, glycans are highly 
heterogeneous, which further complicates analysis in complex samples. Lectin 
enrichment has been commonly used, but each lectin is inherently specific to one or 
several carbohydrates, and thus no single or collection of lectin(s) can bind to all glycans. 
Here we have employed a boronic acid-based chemical method to universally enrich 
glycopeptides. The reaction between boronic acids and sugars has been extensively 
investigated, and it is well known that the interaction between boronic acid and diols is 
one of the strongest reversible covalent bond interactions in an aqueous environment. 
This strong covalent interaction provides a great opportunity to catch glycopeptides and 
glycoproteins by boronic acid, whereas the reversible property allows their release 
without side effects. More importantly, the boronic acid-diol recognition is universal, 
which provides great capability and potential for comprehensively mapping glycosylation 
sites in complex biological samples. 
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By combining boronic acid enrichment with PNGase F treatment in heavy-oxygen 
water and MS, we have identified 816 N-glycosylation sites in 332 yeast proteins, among 
which 675 sites were well-localized with greater than 99% confidence. The results 
demonstrated that the boronic acid-based chemical method can effectively enrich 
glycopeptides for comprehensive analysis of protein glycosylation. A general trend seen 
within the large data set was that there were fewer glycosylation sites toward the C 
termini of proteins. Of the 332 glycoproteins identified in yeast, 194 were membrane 
proteins. Many proteins get glycosylated in the high-mannose N-glycan biosynthetic and 
GPI anchor biosynthetic pathways. Compared with lectin enrichment, the current method 
is more cost-efficient, generic, and effective. This method can be extensively applied to 
different complex samples for the comprehensive analysis of protein glycosylation. 
A.5 Comprehensive analysis of protein N-glycosylation sites by combining 
chemical deglycosylation with LC–MS 
Reproduced with permission from American Chemical Society 
Chen, W., Smeekens, J.M., Wu, R. Comprehensive analysis of protein N-glycosylation 
sites by combining chemical deglycosylation with LC–MS, Journal of Proteome 
Research, 2014, 13 (3), 1466-1473. Copyright 2014 American Chemical Society. 
 
Glycosylation is one of the most important protein modifications in biological 
systems. It plays a critical role in protein folding, trafficking, and stability as well as 
cellular events such as immune response and cell-to-cell communication. Aberrant 
protein glycosylation is correlated with several diseases including diabetes, cancer, and 
infectious diseases. The heterogeneity of glycans makes comprehensive identification of 
protein glycosylation sites very difficult by MS because it is challenging to match mass 
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spectra to peptides that contain different types of unknown glycans. We combined a 
chemical deglycosylation method with LC–MS-based proteomics techniques to 
comprehensively identify protein N-glycosylation sites in yeast. On the basis of the 
differences in chemical properties between the amide bond of the N-linkage and the 
glycosidic bond of the O-linkage of sugars, O-linked sugars were removed and only the 
innermost N-linked GlcNAc remained, which served as a mass tag for MS analysis. This 
chemical deglycosylation method allowed for the identification of 555 protein N-
glycosylation sites in yeast by LC–MS, which is 46% more than those obtained from the 
parallel experiments using the Endo H cleavage method. A total of 250 glycoproteins 
were identified, including 184 membrane proteins. This method can be extensively used 
for other biological samples. 
A.6 Systematic and site-specific analysis of N-sialoglycosylated proteins on the cell 
surface by integrating click chemistry and MS-based proteomics  
Reproduced with permission from The Royal Society of Chemistry 
Chen, W., Smeekens, J.M., Wu, R. Systematic and site-specific analysis of N-
sialoglycosylated proteins on the cell surface by integrating click chemistry and MS-
based proteomics, Chemical Science, 2015, 6, 4681-4689. Copyright 2015 Royal Society 
of Chemistry. 
 
Glycoproteins on the cell surface are ubiquitous and essential for cells to interact 
with the extracellular matrix, communicate with other cells, and respond to 
environmental cues. Although surface sialoglycoproteins can dramatically impact cell 
properties and represent different cellular statuses, global and site-specific analysis of 
sialoglycoproteins only on the cell surface is extraordinarily challenging. An effective 
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method integrating metabolic labeling, copper-free click chemistry and mass 
spectrometry-based proteomics was developed to globally and site-specifically analyze 
surface N-sialoglycoproteins. Surface sialoglycoproteins metabolically labeled with a 
functional group were specifically tagged through copper-free click chemistry, which is 
ideal because it is quick, specific and occurs under physiological conditions. Sequentially 
tagged sialoglycoproteins were enriched for site-specific identification by mass 
spectrometry. Systematic and quantitative analysis of the surface N-sialoglycoproteome 
in cancer cells with distinctive invasiveness demonstrated many N-sialoglycoproteins up-
regulated in invasive cells, the majority of which contained cell adhesion-related 
domains. This method is very effective to globally and site-specifically analyze N-
sialoglycoproteins on the cell surface, and will have extensive applications in the 
biological and biomedical research communities. Site-specific information regarding 
surface sialoglycoproteins can serve as biomarkers for disease detection, targets for 
vaccine development and drug treatment. 
A.7 Systematic investigation of cellular response and pleiotropic effects in 
atorvastatin-treated liver cells by MS-based proteomics  
Reproduced with permission from American Chemical Society 
Xiao H., Chen, W., Tang, G.X., Smeekens, J.M., Wu, R. Systematic investigation of 
cellular response and pleiotropic effects in atorvastatin-treated liver cells by MS-based 
proteomics, Journal of Proteome Research, 2015, 14 (3), 1600-1611. Copyright 2015 
American Chemical Society. 
 
 For decades, statins have been widely used to lower cholesterol levels by 
inhibiting the enzyme HMG Co-A reductase (HMGCR). It is well-known that statins 
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have pleiotropic effects including improving endothelial function and inhibiting vascular 
inflammation and oxidation. However, the cellular responses to statins and corresponding 
pleiotropic effects are largely unknown at the proteome level. Emerging mass 
spectrometry-based proteomics provides a unique opportunity to systemically investigate 
protein and phosphoprotein abundance changes as a result of statin treatment. Many 
lipid-related protein abundances were increased in HepG2 cells treated by atorvastatin, 
including HMGCR, FDFT, SQLE, and LDLR, while the abundances of proteins involved 
in cellular response to stress and apoptosis were decreased. Comprehensive analysis of 
protein phosphorylation demonstrated that several basic motifs were enriched among 
down-regulated phosphorylation sites, which indicates that kinases with preference for 
these motifs, such as protein kinase A and protein kinase C, have attenuated activities. 
Phosphopeptides on a group of G-protein modulators were up-regulated, which strongly 
suggests that cell signal rewiring was a result of the effect of protein lipidation by the 
statin. This work provides a global view of liver cell responses to atorvastatin at the 
proteome and phosphoproteome levels, which provides insight into the pleiotropic effects 
of statins. 
A.8 Systematic study of the dynamics and half-lives of newly synthesized proteins 
in human cells 
Reproduced with permission from The Royal Society of Chemistry  
Chen, W., Smeekens, J.M., Wu, R. Systematic study of the dynamics and half-lives of 
newly synthesized proteins in human cells, Chemical Science, 2016, 7, 1393-1400. 




Protein dynamics are essential in regulating nearly every cellular event, and 
aberrant proteostasis is the source of many diseases. It is extraordinarily difficult to 
globally study protein dynamics and accurately measure their half-lives. Here we have 
developed a chemical proteomics method integrating protein labeling, click chemistry 
and multiplexed proteomics, which overcomes current challenges with existing methods. 
Labeling with both azidohomoalanine (AHA) and heavy lysine allows us to selectively 
enrich newly synthesized proteins, clearly distinguish them from existing proteins, and 
reduce the impact of heavy amino acid recycling. Moreover, multiplexed proteomics 
enables us to quantify proteins at multiple time points simultaneously, thus increasing the 
accuracy of measuring protein abundance changes and their half-lives. Systematic 
investigation of newly synthesized protein dynamics will provide insight into proteostasis 
and the molecular mechanisms of disease. 
A.9 Quantification of tunicamycin-induced protein expression and N-glycosylation 
changes in yeast 
Reproduced with permission from The Royal Society of Chemistry 
Xiao, H., Smeekens, J.M., Wu, R. Quantification of tunicamycin-induced protein 
expression and N-glycosylation changes in yeast, Analyst, 2016, 141, 3737-3745. 
Copyright 2016 Royal Society of Chemistry. 
 
Tunicamycin is a potent protein N-glycosylation inhibitor that has frequently been 
used to manipulate protein glycosylation in cells. However, protein expression and 
glycosylation changes as a result of tunicamycin treatment are still unclear. Using yeast 
as a model system, we systematically investigated the cellular response to tunicamycin at 
the proteome and N-glycoproteome levels. By utilizing modern mass spectrometry-based 
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proteomics, we quantified 4259 proteins, which nearly covers the entire yeast proteome. 
After the three-hour tunicamycin treatment, more than 5% of proteins were down-
regulated by at least 2 fold, among which proteins related to several glycan metabolism 
and glycolysis-related pathways were highly enriched. Furthermore, several proteins in 
the canonical unfolded protein response pathway were up-regulated because the 
inhibition of protein N-glycosylation impacts protein folding and trafficking. We also 
comprehensively quantified protein glycosylation changes in tunicamycin-treated cells, 
and more than one third of quantified unique glycopeptides (168 of 465 peptides) were 
down-regulated. Proteins containing down-regulated glycopeptides were related to 
glycosylation, glycoprotein metabolic processes, carbohydrate processes, and cell wall 
organization according to gene ontology clustering. The current results provide the first 
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